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ABSTRACT 
Gn1actokinase deficiency .. 'is an autosomal-recessive inborn error of galactose metabolism 
whose major clinical manifestation is the development of cataracts during the first months 
of life. This metabolic disorder is caused by defects in the first enzyme of the Leloir 
pathway, galactokinase, encoded by the gene GALKJ on chromosome 17q24. Despite the 
identification of a number of conserved domains in GALKJ, understanding of the 
functional significance of these regions and the molecular basis of the disorder is limited. 
This is largeiy due to the rarity of the disease and the fact that the small number of CALK! 
mutations identified to-date are confined to individual families, thus precluding extensive 
genotype/phenotype correlations. 
The current investigation involved an analysis of the GALKI gene in nine patients with 
biochemical phenotypes indicative of classical galactokinase deficiency. Sequencing of the 
entire coding region, flanking intronic sequence and both the 5' UIR and 3 UTR of 
CALK! using Dye Tenninator chemist!}' and the ABI377 DNA Analyzer, revealed four 
novel mutations in two unrelated patients with galactokinase deficiency. Three of these 
were amino acid substitutions: 1569C--> Tin exon 2 (R68C), 7093C--> Tin exon 6 (f288M) 
and 7538G-->C in exon 8 (A384P). In addition, a single base deletion was found in exon 5 
(2833delC), predicted to result in a shift of the reading frame and a premature termination 
codon at posicion 263. Sequence analysis in a third patient detected a 563C_.,A 
transversion (P28T), previously identified as a common mutation in six Bulgarian Gypsy 
families (Kalaydjieva et al., 1999). The remaining six patients, belonging to socially and 
geographitally dispersed Gypsy groups from Spain, Hungaty and Bulgaria were screened 
for P28T using a PCR-based Ava! restriction assay. All were homozygous for P28T. 
Haplotype analysis established a common origin of the mutation, providing further 
11 
evidence that P28T is a founder mutation among patients with Gypsy edmicity and 
signaling the mutation is more widespread than initial indications suggest. 
To detennine the carrier frequency and distribution of the P28T mutation, 227 unrelated 
individuals originatir.g from various Gypsy groups in Europe, were screened using the A val 
assay. Carrier frequency in the Vlax Roma was calculated at 2.7% and 1.8% in Spanish 
Gypsies. These results indicate that the prevalence of the P28T mutation warrants further 
investigation preceeding the development of newborn screening strategies and dietary 
intervention in these groups in a bid to prevent infantile blindness. The findings also allow 
the identification of a large sample of carriers suitable for future investigations into 
genotype/ phenotype correlations. 
Sequence analysis of the GAL/(1 gene in two Afro/Hispanic patients presenting with a rare 
atypical phenotype with metabolic symptoms of galactokinase deficiency and normal RBC 
galactokinase activity, revealed no plausible disease-causing mutations. In fact, lack of 
similarity in the GALKJ gene in both patients, despite sharing a common ethnic 
background, suggested exclusion of GAUG in this phenotype. 
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CHAPTER! INTRODUCTION 
1.1 Overview 
Galac.tokinase deficiency (Gitzelmann, 1965; Gitzelmann, 1967) is an autosomal 
recessive inborn error of the first step of the Leloir metabolic pathway through which 
galactose enters glycolysis (Frey, 1996). Unlike the .~evere and debilitating symptoms 
associated with other forms of galactosemia (Segal & Berry, 1995), the oniy confirmed 
symptom of galactokinase deficiency is the development of cataracts (Figure 1. 1). In 
homozygotes, these occur within the first weeks to months of life (Levy, Krill, & Beutler, 
1972; Beutler et al., 1973; Stambolian, 1988). There is also evidence to suggest that 
heterozygote carriers of a deficiency causing allele may be at risk of developing presenile 
cataracts (Elman, Miller, & Matalon, 1986; Starnbolian et a!., 1986). The progression to 
sight impairment is caused by the accumulation of an alternative product of galactose 
metabolism, called galactitot which accumulates within the lens of the eye, ultimately 
leading to the rupture and opacification of lens fibers. Fortunately, with early detection and 
intervention with a galactose-restricted diet, cataract formation in affected individuals can 
be prevented and the pathological changes in the lens can be reversed in some cases 
(Olarnbiwonnu, McVie, Ng, Frasier, & Donnell, 1974). 
Elucidating the molecular basis underlying galactokinase deficiency began in 1995 
with the cloning of the gene GALKI (Starnbolian et al., 1995) and its mapping to the 
chromosomal location 17q24 (Starnbolian et al., 1995; Kalaydjieva et al., !999). Despite 
this, only a limited amount of knowledge exists in regards to the functional organization of 
GAL/(1 and conclusive information about the genetic regulation of galactokinase 
expression is yet to be fully obtained. Investigations of the molecular basis of galactokinase 
deficiency can contribute such informacion. However, these studies are hampered by the 
low frequency of the disorder and by the fact that the small number of identified mutations 
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Figure 1.1 "Oil-droplet"cataract in three-month-old child with galactokinase 
deficiency. (Source: Campolattaro, 2000) 
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arc confined to single f;unilies, thus precluding reliable genotype-phenotype correlations. 
What is known is that the CALK/ gene spans approximately 7.3kb of DNA and is 
arranged into 8 cxons that code for a mRNA transcript of 1.35kb {Bergsma ct al., 1996). 
Ex on 1 encodes a highly conserved signature sequence common to galactokinascs in a wide 
r.mge of orgmisms. The function of this shared region of homology remains unknown, but 
mutations within this sequence have been associated with the deficiency phenotype 
(Stambolian et al., !995; Kalaydjieva et al., 1999; Kolosha et al., 2000) suggesting that this 
area of the gene has a critical role in the normal function of the encoded enzyme. Other 
highly conserved areas include exons 3 and 7, which both encode A TP binding motifs 
essential for the phosphorylating activity of galactokinase. Again, mutations within these 
exons have been identified and linked to the deficiency phenotype (Asada et al., 1999; 
Kolosha et al., 2000). The function of the remaining coding regions of GALKI and how 
they affect the activity of the galactokinase protein remain to be determined. Mutation 
analysis of DNA samples from galactokinase-deficient individuals and comparison with the 
wild-type allele, offers a useful tool for elucidating the role that regions within the gene play 
in the structure and function of the encoded enzyme. 
An opportUnity to add to the known mutations of GALKI and the possibility of 
gaining an understanding of the regulatory mechanism of the gene has arisen as a result of 
collaboration between the Centre for Human Genetics at Edith Cowan University, the 
Department of Pediatrics at Harvard University Medical School, USA, the University 
Children's Hospital in Zurich, Switzerland, the Department of Pediatrics at the Medical 
School in Szeged, Hungary and the Insritut Bioquimica Clinica in Barcelona, Spain. The aim 
is to sequence the GALJ(J gene in patients who exhibit biochemical findings typical of 
galactokinase deficiency. This analysis may provide new information about the molecular 
pathology underlying the condition and about the function of the encoded protein domains. 
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A number of these patients are of Gypsy ori&ins. Analysis of the GALKI gene in such 
individuals wi11 provide information on the homo/heterogeneity of the molecular basis of 
galactokinase deficiency in this population, known to have a high frequency of the disorder. 
The identification of a common mutation, P28T (Kalaydjicva ct al., 1999) will allow a study 
of the history of the mutation. It will also open the way to the detection of large numbers of 
genetically homogenous affected individuals and carriers which, in tum, will allow future 
studies of genotype-phenotype correlation and of the role of GALKl in presentle cataracts. 
In addition to these individuals, a new sample of patients has been identified who 
share elevated plasma galactose levels and galactitol production analogous to the deficiency 
phenotype, yet whose biochemical assays reveal no discernible loss of function to any of the 
red blood cell enzymes involved in the Leloir pathway. These clinical observations question 
existing concepts of galactose metabolism) in particular casting doubt upon the presumption 
that measurement of erythrocyte enzyme expression reflects adequately the phenotype. The 
possibility that multiple forms of the galactokinase enzyme exist is supported by age and 
tissue-related differences in enzyme expression levels (Ng, Donnel, & Bergren, 1965; Shin-
Buerhring, Beier, Tan, Osang, & Schaub, 1977), variation in kinetic propenies between 
galactokinase from adult and fetal/newborn sources (Cuatrecasus & Segal, 1965; Mathai & 
Beutler, 1967; Magnani, Cucchiarini, Stocchi, Dacha, & Fornaini, 1982b) and discrepancies 
between biochemical phenotype and genotype in some affected individuals (Kalaydjieva et 
al., 1999). 
Whether these observations can be attributed to two forms of galactokinase encoded 
by separate genes, or reflect post-translational modifications, or alternative transcripts of 
the same gene, remains to be seen. The study of the GALKI gene in patient:. with 
metabolic e\idence of galactokinase deficiency yet normal RBC enzyme activity, may 
provide an answer to some of these questions. 
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1.2 Significance of the study 
l11e study of the molecular basis of galactokinase deficiency is important for a number of 
reasons including; 
1.2.1 Adding knowledge to the structure and function ofGALK1 
An important outcome from this investigation is the possibility of adding to the 
limited knowledge concerning the molecular organization and function of GALKI. 
While some aspects of the coding region of GALKJ are known, the role of other 
regions within the gene and how they detennine the structure and hence function 
of the enzyme remain relatively unknown. The identification of mutations and 
correlation with the disease phenotype will provide information mto the 
importance of these genomic areas to normal galacrokinase expression. 
1.2.2 Understanding the mechanisms of spread of common founder 
mutation(s) in GALK1 and identification of high-risk groups 
There is evidence suggesting wide ethnic variation in the incidence of galactokinase 
deficiency, with a higher frequency among subjects of Gypsy origin. Investigations 
into the molecuhr epidemiology of the disorder will provide an insight into the 
nature and mechanisms of spread of the underlying mutations, and will identify the 
Gypsy populations where early neonatal detection and dietary treatment will 
prevent childhood blindness. 
1.2.3 Possible links to presenile cataract formation 
Further benefits derived from the understanding of galactokinase expression and 
funr.r.ional domains would not only be limited to homozygote sufferers. There is 
also evidence to suggest that heterozygote carriers of a deficiency·causing allele may 
be at risk of developing presenile cataracts (Starnbolian et al., 1986). When we 
consider that heterozygote frequency for galactokinase deficiency has been 
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estimated to fall within the ranges of approximately 1 in 100 (Mayes & Guthrie, 
1968) to 1 in 300 individuals (Tedesco et al., 1975), the relationship between carriers 
and presenile catarad formation may point towards partial galactokinase deficiency 
as a significant contributor to the overall frequency of cataract cases in the wider 
population. Thus, understanding the genetic regulation of galactokinase expression 
would have great implications in the development of intervention strategies, in 
particular the extent that pre~clinical testing and dietary measures would need to be 
taken in susceptible individuals. 
1.3 Research ainlS 
The aims of the research consist of the following: 
1. To study the molecular basis of classical galactokinase deficiency through; 
a) Identification of novel mutations and polymorphism in the GAL!(] gene. 
b) Analysis of the history and frequency of common mutation{s) in the 
GALKI gene. 
ii. To investigate the role of CALK/ in the development of an atypical phenorype 
with metabolic symptoms of galactokinase deficiency and normal RBC activity. 
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1.4 Operational terms and definitions 
A, C, T, G Adenine, Cytosine, Thymine, Guanine 
ABI Applied Biosystcms I ncorporatcd 
A 1P Adenosine triphosphate 
Bp Base pairs 
eDNA Complimentary deoxyribonucleic acid 
CpG Dinucleotide with a cytosine at the 5' end connected by a phosphodiester bond 
to a guanine at the 3' end. Mutational hotspot due the susceptibility of cytosine 
to undergo methylation and deamination to thymine. 
Da Daltons 
ddNTPs Dideoxynucleotide triphosphates 
DNA Deoxyribonucleic acid 
dNIPs Deoxynucleotide triphosphates 
GALKl Galactokinase gene 
kb Kilo bases 
KM Michaelis constant 
mRNA Messenger ribonucleic acid 
MgCI2 Magnesium chloride 
mM Millimolar (10 _,) 
nM Nanomole (10 -~ 
PCR Polymerase chain reaction 
RBCs Red Blood Cells 
RNA Ribonucleic acid 
S'UIR 5' Untranslated region 
3'UIR 3' Untranslated region 
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CHAPTER2 LITERATURE REVIEW 
2.1 Galactokinase 
2.1.1 Galactokinase and the Leloir pathway 
The function of the Leloir pathway of metabolism is to convert galactose into 
glucose-6-phosphate in preparation for utilization in glycolysis, glycogenesis or 
incorporation into nomtal cellular complex carbohydrates (Frey, 1996). In mammals, the 
main dietmy source of galactose is the hydrolytic breakdown of milk-sugar into the 
monosaccharides glucose and galactose. Galactose then enters the Leloir pathway where it 
undergoes phosphorylation by galactokinase to fonn galactose·l·phosphate (Figure 2.1). 
Gak.wse·l-p/nsp:ue 
Galacwkinase 1f1il:#rran.ferase 
Galactose ( ") ., Ga1actose-1-phosphate ~ Gluctose-6-phosphate 
A TP ADP UDP-glu '!,..__/ UDP-G.ll 
Figure 2.1 Role of galactokinase in the Leloir pathway 
The function and expression of this enzyme has been characterized in a number of 
organisms, including bacteria (Wilson & Hogness, 1969), mice (Ai et al., 1995), rat 
(Cuatrecasus & Segal, 1965), porcine liver (Ballard, !966), as wetl as various human tissues 
including etythrocytes, leukocytes, placenta (Srivastava, Blume, Van Loon, & Beutler, 
1972) and fibroblasts (Friedman, Yarkin, & Merril, 1974). The most significant galactose 
conversion occurs within the liver, where expression levels of galactokinase are 
approximately 50 times higher than those in other tissue sources (Shin-Buerhring, Beier, 
Tan, Osang, & Schaub, 1977). Uptake of galactose from the bloodstream by the liver is a 
highly efficient process (Goresky, Bach, & Nadeau, 1973) mediated by two factors, firstly, 
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the movement of galactose across the hepatocyte membrane by the presence of GLVT2 
transporters {Burchell, 1994) and secondly, its conversion to galactosc-1-phosphate by 
ga1actokinase. Such is the efficiency of this process, that galactose has been used to 
measure hepatic function and blood flow in physiological studies (Henderson & Hanna, 
1983). The other significant site of net removal and utilization of galactose is in the 
erythrocyte. Here, galactose is used as an energy source via its conversion to glucose-6-
phosphate and entry into the glycolytic pathway. Although galactokinase from both 
erythrocytes and liver catalyzes the same reaction} the utilization of the end metabolic 
product differs. It is not surprising therefore that a number of differences exist berween 
the levels of activity and kinetic properties of the liver and RBC enzyme, some of which 
have been interpreted as evidence of the existence of multiple forms of the enzyme 
(Cuatrecasus & Segal, 1965; Ng et al., 1965; Mathai &Beutler 1967). 
2.1.2 Age and tissue-related differences in gttlactokinttse expression 
Measurement of galactokinase in individuals of v.ulous ages suggests that enzyme 
activity is considerably higher during infancy than later in life (Ng et al., 1965). In fact, up to 
a period of three years after binh, galactokinase activity is nearly 3 times higher than that of 
older children and adults. This may in part reflect changes from the early nutritional intake 
of galactose derived from breast milk to a more varied diet in adulthood. The high 
expression of galactokinase in infancy may reflect the important role galactose may have as 
an energy source in early development and growth. 
Galactokinase is found to differ between fetal liver} kidney, lung, spleen, muscle and 
brain in regards to substrate afftnity as well as duration and degree of expression (Shin-
Buerhring et al., 1977). Enzyme activity in liver increases in a linear progression with 
gestational age, reaching its maximal peak by 28 weeks. Expression within the brain 
however, remains constant for the first 5 months of prenatal development before increasing 
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to preterm levels. These observations suggest that independent or tissue·specific regulation 
of galactok.in;lSe expression may be occurring between these tissue sources based upon the 
substrate needs of e;Kh tissue type. 
Other tissue differences are noted when galactok.inase isolated from placenta is 
compared to both the livec and erythrocyte enzyme (Table 2.1). These differences refer to 
kinetic properties of the enzyme, as well as to the physical characteristics of the protein. 
Table 2.1 
Galactokinase Properties in Various Tissue 
Km galactose 
KmATP 
Inhibition by G-1-P 
~ Srivastava rt al .. (1972) 
b Blume and Beuder (1971) 
c Cuatrecasas and Segal (1965) 
Note. Liver properties measured in rat 
2501JM 
JOO~M 
High 
100-150 ~M 
200-SOO~M 
nil 
Fetal/ newborn> adult 
Fetal/newborn> adult 
Fetal/newborn> adult 
Other differences are noted in the functional role of galactokinase. It has been 
suggested that galactokinase in liver can act in a rate·limiting manner that prevents the 
toxic accumulation of galactose-1-phosphate, implicated in the severe pathological 
symptoms observed in other defects of galactose metabolism (Segal & Beny, 1995). 
Evidence supporting this function comes from sustained galactose loading in rat liver 
(Rogers, Bovee, Saunders, & Segal, 1989) and human liver-derived cell lines (Davit-Spraul, 
Pourci, Soni, & Lemonnier, 1994), where galactokinase activity declines in response to 
chronic overloading as a result of the inhibition by galactose-1-phosphate. This rate-limiting 
role is not evident in human erythrocytes (Mathai & Beutler, 1967) suggesting that this 
function is limited to the liver form of the enzyme. The rate-limiting role of liver 
galactokinase is age-dependent (Cuatrec.sus & Segal, 1965), with fetal galactokinase 
inhibited by galactose-1-phosphate more than the adult enzyme. Other differences noted in 
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this investigation include greater stability and a ga1actosc KM approximately 4 times higher 
in fetal galactokin•tse compared to the adult enzyme. 
Further evidence of age-related differences in kinetic properties comes from 
comparative studies between adult and fetal erythrocytes. Mathai and Beutler (1967) found 
slight but statistically significant evidence for a fetal RBC. galactokinase with higher KM for 
galactose than that derived from adult sources. This observation remains when the age-
related differences in erythrocyte composition are accounted for (Magnani et al., 1982b), 
such as the separation of both fetal and adult red blood cells into fractions of different 
mean ages by density gradient ultracentrifugation prior to measuring galactokinase activity. 
This technique offers a more accurate indication of enzyme activity by accounting for the 
inverse relationship between erythrocyte life-span and enzyme levels. Funher findings by 
Magnani et al. (1982b) include a fetal erythrocyte galacrokinase with specific activity three 
times higher than the adult enzyme (Table 2.2) and displaying considerably greater 
thermostability than the galactokinase derived from adult erythrocytes. 
Table 2.2 
Properties of Galactokinase in Adult and Fetal EQ'!hrocytes 
Molecular weight 
Specific activity 
KM galactose 
KMATP 
• Magnani et a!. (1982b) 
Erythrocyte galactokinase• 
Fetal Adult 
48 000 48 000 
39.5 mU/gHb 12.7 mU/gHb 
215 ~M 113 ~M 
400~M 320 ~M 
2.1.3 Differenc., in the physical properties of the enzyme 
Differences in the physical properties of galactokinase are also known to exist. 
Srivastava et a!. (1972) describe a placental galactokinase with a larger molecular weight 
than that derived from adult erythrocytes. Tooesco et a!. (1973) provide a description of 
erythrncyte galactokinase isolated from one individual that has higher electrophoretic 
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mobility omd higher enzyme activity than that found in erythrocytes from adult controls. 
The kinetic properties are similar to placental galactokinase, suggesting a persistent 
expression of a fetal fonn of the enzyme. 
Conclusive information about the differences in molecular structure that would 
account for these observations is lacking. An early investigation into the physical makeup 
of galactokinase derived from erythrocytes suggested a dimeric structure consisting of two 
monomers of molecular weights 25 OOODa to 27 OOODa (Blume & Beutler, 1971). A 
succeeding study, using a much more effective technique of protein purification, found no 
evidence for a dimeric structUre in either erythrocytes or placental ga1actok.inase 
(Starnbolian, Scarpino-Myers, & Harris, 1985). In fact, the latter study reports the 
monomeric galactokinase from both sources as having a molecular weight of approximately 
38 OOODa, significantly lower than previously thought (Srivastava eta!., 1972). This, again, 
contrasts with an analysis of eDNA derived from osteoclastoma and T-ee!! eDNA libraries 
(Starnbolian eta!., 1995): based upon the nucleotide sequence, the molecular weight of the 
encoded galactokinase from these sources is predicted to be 42 271 Da. 
2.1.4.41/e/ic variation and genotype/phenotype differences 
Allelic variations from the recognized wild-type GKA/GKA genotype have been 
identified and point towards polymorphism between populations. The Philadelphia variant, 
GK, (Tedesco et a!., 1977) is found in high frequency amongst the African/ American 
population {Soni, Brivet, Blanc, Jaeger, & Lemonnier, 1988) and causes reduced 
galactokinase activity in RBCs, yet normal levels of enzyme e."Xpression and function in 
leukocytes. Another suggested allelic variation is the Urbina variant {Magnani, G.tcchiarini, 
Dacha, & Fomaini, 1982a). This gal acto kinase has reduced catalytic properties, decreased 
in'Uiw stability and a lower KM for A TPMg'" than the enzyme encoded by both the wild-
type, GKA and some deficiency-causing; GKc alleles. It is possible that the degree and 
range of allelic variants may in fact be more widespread than those already characterized. 
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Other genotype/ phenotype discrepancies have been detected that may support 
heterogeneity in galactokinase expression. An interesting observation in a kindred studied 
by Kalaydjieva ct al. (1999) was the biochemical findings of an individual homozygous for 
the P28T mutation who displayed intermediate erythrocyte galactokinase activity analogous 
to a heterozygote cotrrier. This particular individual reported a history of juvenile cataracts 
suggesting a lack of enzyme activity at an early age. Why this person is now expressing 
galactokinase despite being homozygous for the deficiency causing mutation is unclear. It 
has been suggested that this intermediate activity may represent expression of an adult form 
of the enzyme. Whether this expression is due to the existence of another gene or age-
related differences ir. the expression of the GALKJ encoded protein is unknown. 
It remains unclear whether the age and tissue-related differences in levels of activity, 
kinetic properties and physical characteristics are the product of differences in the 
regulation of expression and/ or post-translational modification of a single gene product or 
whether they result from the existence of more than one galactokinase gene. 
2.2 Galactokinase Deficiency 
2.2.1 Clinical synopsis and symptoms 
In 1933 Fanconi, as cited in Gitzelmann (1965), first described "galactose diabetes", a 
term used to denote an aberration of galactose metabolism, whose only symptom was the 
development of early-onset cataracts. The exact enzyme defect was not confirmed until 
Gitzelmann (1965) measured erythrocyte galactokinase in a patient first diagnosed by 
Fanconi, and found negligible enzyme activity. It is now recognized that deficiency of 
galactokinase can cause the formation of juvenile cataracts in homozygotes. 
Cataracts remain the only confirmed symptom of the disorder, despite isolated 
reports of neurological impairment (Pickering & Howell, 1972) hepatosplenomegaly 
(fhalhammer, Gitzelmann, & Pantlitschko, 1968), neurofibromatosis (Gitzelmann, 1965) 
and pseudotumor cerebri {Litman, Kanter & Finberg, 1975). 
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Biochemical assays in galactokinase·dcficicnt individuals reveal elevated plasma levels 
of galactose, called hypcrgalactosernia, the presence of unrnetabolized galactose in the urine, 
known as galactosuria, and the presence of a sugar poly! in both urine and tissue called 
galactitol (Gitzelmann & Hansen, 1980). It is galactitol, the product of an alternative 
pathway of galactose metabolism, that is implicated in causing the degenerative changes to 
the lens of the eye. The pathological progression to cataract formation in humans occurs 
due to the influence of a number of interacting processes initiated by high intake of dietary 
galactose. When galactose levels are elevated, aldose reductase within the lens of the eye 
catalyzes the conversion of galactose to galac.titol. Galactitol cannot be further metabolized 
by the body and as a result accumulates within the lens. This causes osmotic changes in the 
optic fluid, causing the disruption of cell membranes and ultimately the opacification of lens 
fibres. This mechanism is evident in galactokinase·deficient strains of mice transfected with 
the human aldose reductase (hAR) gene (Ai et al., 2000). These transgenic mice, when fed a 
high galactose diet rapidly develop cataracts. This is in contrast to wild·type galactokinase· 
deficient mice where aldose reductase activity within the lens is negligible. These 
observations suggest that it is the high intake of galactose, in conjunction with a deficiency 
in galactokinase, on a background of aldose reductase expression in the lens, that results in 
the development of cataracts. 
2.2.2 Epidemiology 
The I".mge and incidence of galactokinase deficiency (fable 2.3) varies widely berween 
populations. Across USA, Japan and Western Europe newborn screening has only detected 
6 cases amongst 6 million births (Levy, 1980). By contrast, data from Austria, Germany and 
Bulgaria suggest a higher incidence ranging from approximately 1: 52 000 to 1: 157 000 
births {Gitzelmann & Hansen, 1980; Kalaydjieva et a!., 1999). The highest frequency has 
been found among the Vlax Roma, with one affected homozygote per 1 in 1600-2500 
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binhs. The high incidence has been attributed to a founder mutation segregating in this 
isolate {Kalaydjieva eta!., 1999). 
Table 2.3 
Variation in Incidence and Allele Frequency 
Homozygotes 
Heterozygotes 
Incidence/Frequency 
I d 000000 
1 ' 157 000 
L 153 000 
1,52000 
1 ' 1600. 1, 2500 
1 'so 
1' 107 
LJ04 
Region/Population 
USA, Asia, Europe 
Germany 
Austria 
Bulgaria 
VlaxRoma 
Caucasian 
Caucasian 
Caucasian/Nth American 
Source 
Levy (1980) 
Gitzelnunn & Haruen (1980) 
Gitzelmann & Hansen (1980) 
KalaydjiP.va et al .. (1999) 
Kalaydjieva et al .. (1999) 
Gitzelmmn (1967) 
Mayes & Guthrie (1968) 
Ted,co e1 ol .. (1975) 
Early studies that measure erythrocyte galactokinase activity in adults suggest that the 
heterozygote carrier frequency of a deficiency allele falls in the range between 1 in 50 
(Gitzelmann, 1967) to 1 in approximately 100 individuals {Mayes & Guthrie, 1968). The 
predicted frequency of affected births from these estimates is considerably higher than that 
actually detected by newborn screening programs. 
The above studit:s are based on the detection of heterozygous earners by 
measurement of RBC enzyme activity, with some inherent problems. On one hand, enzyme 
activity fluctuates widely and is an unreliable indicator of carrier status. Furthermore, the 
results can be affected by variations in methodology, increasing further the error range. In 
addition, it is unclear to what extent RBC activity reflects the organism's ability to 
n.etabolize galactose. 
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It is possible that other factors may be involved in this discrepancy, including 
miscalculation of heterozygote frequency due to the presence of allelic variants of 
galactokinase. The aforementioned Philadelphia variant (Section 2.1.4) is one such allele in 
the African/ American population that causes a reduction in erythrocyte activity yet normal 
expression in other tissue sources (Tedesco et al., 1973; Tedesco et al., 1975). No 
detrimental effects are associated with this genotype. It is possible that early studies that 
relied upon erythrocyte assay to detennine galactokinase activity may have inadvertently 
measured similar allelic variants unknown at the time of the study, therefore overestimating 
heterozygote frequencies for the deficiency allele. 
Other considerations that may account for these discrepancies include the possibility 
of the existence of two f01ms of the galactokinase enzyme, one expressed during early 
development and childhood, the other during adulthood. Therefore if heterozygote 
frequencies have been calculated from adult samples based upon erythrocyte expression 
alone, the enzyme measured may not be the galactokinase involved in the infantile 
deficiency. Given the differences in galactokinase properties and expression patterns as a 
function of age {Section 2.1.2), this second explanation appears plausible. 
2.2.3 Possible role of galactokinase deficiency in presenile cataract formation 
The pathological progression to cataract formation may not be restricted to 
homozygote sufferers. It has been suggested that heterozygote carriers of a deficiency allele 
may be at risk of developing cataracts during the 2"' to s•h decade of life {Starnbolian et a!., 
1986). Other studies fmd no such relationship {Magnani, Cucchiarini, Stocchi, & Dacha, 
1983). The reasons for these_discrepant findings :u-c unclear. One possible explanation is 
differences in galactose content in the diet, where a high intake can contribute to cataract 
formation. This may be due to the fact that erythrocyte galactokinase assay of individuals 
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carrying only one functioning allele reveal galactokinase activity at approximately 50% of 
normal {Sit:nnann & Kaloud, 1976). Thus, sustained levels of galactose in the diet may 
overload the net conversion of galactose to ga1actosc-1-phosphate, in turn promoting the 
formation of galactitol and with it the disrupriom to lens integrity. 
The effects of increased dietary ima1~e of galactose coupled with reduced 
galactokinase activity and its role in cataract fonnation is also supponed in an investigation 
of maternal enzyme levels during pregnancy (Harley, Mutton, Irvine, & Gupta, 1974). llis 
study found that galactok.inase was significantly reduced in mothers whose children have 
congenital cataracts, despite these children having normal erythrocyte enzyme expression 
levels and activity. Tills suggests that marginal maternal deficiency of galactokinase coupled 
with an increase in lactose intake during pregnancy may exceed the maternal ability to 
effectively metabolize galactose. 
The proposed link between galactok.inase deficiency and presenile cataract formation 
has never received solid support. Mutation detection would offer a much more direct 
approach to the identification of carriers, however this has been hampered by the low 
incidence of the disorder and the private nature of most of the GALKJ mutations identified 
thus far {Section 2.4). It is the through the identification of populations at high risk, where a 
single common founder mutation ocrurs at a high frequency that will allow a large number 
of carriers to be identified. The relationship between pattial galactokinase deficiency and 
presenile cataract could thus be investigated. 
2.3 The GALKJ gene: Localization and Structure 
23.1 Localization 
The localization of the gene encoding galactokinase on the long arm of chromosome 
17 was first determined using somatic cell hybridization by Elsevier eta!. {1974). In 1995, 
physical Imppingusing fluorescent in-situ hybridization (FISH) ?laced the GALKI gene on 
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band 17q24 (St.unbolim et .U., 1995). Further refinement of this position to within a 1 eM 
distance wo1s achieved using linkage ana1ysis and radiation hybrid mapping by Kalaydjicva ct 
al. (1999). The earlier identification in 1992, of a eDNA from a gene called GK2 wl'ich 
shared similar characteristics to galactokinase, questioned the exact chromosomal 
assignment of the galactokinase gene (Lee, Peterson, Caiman, Herskowitz, & O'Dunnell, 
1992). However a succeeding study (Pastuszak, ODonnell & Elbein, 1996) found that 
.Uthough the protein encoded by GK2 could phosphorylate g.Uactose, this could only occur 
when the substrate was present in millimolar concentrations. Instead, GK2's major role is 
to phosphorylate N-acetylgalactosamine, a component of complex carbohydrates found in 
eukruyotic cells. 
2.3.2 Characterization 
The isolation of GALKI eDNA by Stambolian et .U. (1995) was initi.Uiy based on 
comparisons of the sequences of peptide fragments derived from human placental 
galactokinase, to a number of eDNA libraries and expressed sequence tags (ESTs). 
Significant similarities were found in two human eDNA clones. The analysis of the 
nucleotide sequence of these cDNAs predicted a mRNA product of approximately 1350 
nucleotides. Further studies reve.Ued the full-length genomic organization of GALKJ 
(Bergsma et .U., 1996). The gene spans approximately 7.3kb of DNA and is made up of 8 
exons coding for a mRNA transcript of 1358 nucleotides, in accordance with the transcript 
size isolated earlier by Stambolian et .U. (1995). 
Desrite these an.Uyses, understo~ding of the function.U organization of the GALKI 
gene is limiteri to only a small number of domains (Figure 2.2). Exon I contains a highly 
conserved signature sequence common to a wide range of organisms including bacteria, 
yeast (Stambolian et .U., 1995) mice (Ai et .U., 1995) and humans. The function of this 
shared region of homology remains unknown but a number of mutations within this 
domain have been associated with the deficiency phenotype (Stambolian et a!., 199 5; 
18 
Kahtydjieva et al., 1999; Kolosha et al., 2000), suggesting that this area of the gene has a 
critical role in the normal functioning of the encoded enzyme. Other conserved areas 
include exons 3 and 7, both encoding ATP-binding motifs essential for the phosphorylating 
activity of galactokinase. 
The other remaining area of the human GALKJ gene characterized, includes a 72bp 
sequence of the last exon which has been found to encode the carboxyl tcnninus of the 
galactokinase protein (Bergsma, et al., 1996). 
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2.3.3 5'UTR and promoter region 
The promoter region of GA LK I is found approximately 370bp upstream of ex on 1 
(Bergsma eta!., 1996) and lacks the TATA and CCAAT box motifs thought necessary for 
accurate mRNA initiation (Strachan & Read, 1998). Instead, the S'UlR is characterized by a 
polymerase II promoter with a high GC content, indicative of potential binding sites for the 
Spl transcription factor (fjian, 1995). In fact, three sites for Spl arc recognized. In 
addition, the S'UIR contains a number of possible transcription stan sites downstream of 
the promoter region, positioned between 21 and 61 hp upstream of the first exon (Figure 
2.3). The presence of these multiple mRNA stan sites is attributed to the lack ofTATA and 
CCAA T motifs. An interesting point to make about this observation is that Bergsma et al. 's 
{1996) description of these multiple start sites was derived from the 5' ends of mRNA 
transcripts isolated from placental tissue. It is possible that these start sites are unique for 
the galactokinase produced in this tissue and may not be indicative of the transcriptional 
origin of GALKJ mRNA in other tissue sources. This factor may partly account for the 
different physical and kinetic propenies evident between placental and liver forms cf the 
enzyme. 
Discrepancies exist in the nucleotide sequence of the non·coding regions of GALKJ 
reported by Asada et al. {1999) and by Bergsma et al. (1996). Three nucleotide differences 
have been found in the S'UIR of GALK.l among a small sample of Japanese and Caucasian 
subjects representing both wild type and deficiency phenotypes. This area, although not 
transcribed, has been shown to affect and influence the transcriptional activities of genes 
(Cooper, Kraw=d<, & Antonarakis, 1995). These differences may reflect polymorphisms, 
however given the limited number of sannples analyzed, this possibility is unclear. Other 
discrepancies noted by Asada et al. {1999) include several nucleotide re-arrangements in 
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introns 1, 2 and 5. A 20bp tandem repeat was also found in intron 5 that had not been 
previously detected by Bergsma et al. (1996). As with the differences noted in the 5'UTR, it 
couJd not be confirmed whether these are the result of polymorphisms unique to the 
population studied or in fact reflect errors in the published sequence. 
5' 
-481 CTGATG,-\CCT CTCAC:\GCTG CTGGCCCTGG GGACCTAGGG GATCCCTTTG 
-431 GGfu-\.TCCCAG GTCfu-\CCGGG TGCC;\GCTCC ATTGCTCTGG CTGTGTGGGT 
-381 GGTGGTGGGT GGTG'"\GGCAC ATAGAAAGTC ACCAGCGCCA GGGAAGGGCA 
-331 GCTCAGAAAT CCTGGTCATG CCAAGTGCCA CTCAGGGCTA TTCTCACTCT 
.G. 
-281 AGTGAGTGCT CATTGGTTCT TCCCGAAGTC CAGAGGGAAG GAC \ CCATCG 
-231 GGGGCGCTGT ATCCCACCCG GCACCATTAG CCCCTGCCAC CCACCACCCA 
-181 GCAGCTGGAT TCCCACGGGA GTTGCGGGTG GGGGCGGAAC CGGCTGAGGT 
-131 CTGGGGGCGG GGCGTCCGGG CGCGGGGCGG GGCT GGCGGG AATGTGCGCA 
~ ~ 
-81 CCCCCGCGCG GGGCTCCTCC CGAGCATCCC GCGCCGACGG GGCTGTGCCG 
.. .. .. ........ .. .. 
-31 GAGCAfCT~T GCAGAGCTGC AGGCGCGCGT cl ATG GCT GCT TTG AGA 
• £ met ala ala leu arg 
exon 1 
.A. multiple transcription start sites 
- binding sequence for Sp1 transcription factor 
Bold face type denotes polymerase II promoter sequence 
G Base discrepancy detected by Asada et al.. (1999) 
Figure 2.3 GALK1 5'UTR• 
• Adapted from Bergsma et al.. (1996) 
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2.4 Mutations in GALKI associated with enzyme deficiency 
Due to the low incidence of galactokinase deficiency, only a small number of patients 
have been available for mutation analysis, therefore the number of mutations identified and 
characterized in the GALKI gene remains small (Figure 2.4). To-date, only 20 mutations 
have been reported among 32 individuals with gal.actokinase deficiency {Stambolian et al., 
1995; Kalaydjieva et al., 1999; Asada et al., 1999 & Kolosha et al., 2000). The origins and 
ethnicity of these patients are diverse and include individuals of European/ American, 
Japanese, Turkish, Afro/ American, Hispanic, German, Swiss, Costa Rican and Vlax Gyfey" 
descent. The majority of these mutations are confined to individual families and as a result 
hamper meaningful genotype-phenotype correlations and also impede research into the link 
between partial deficiency and presenile catilract formation. The private nature of these 
mutations also determines that effective mutation testing in most populations for both 
newborn screening and mass detection of carriers is not feasible. 
Mutations published to-date are shown in Table 2.4 and include 9 missense mutations 
and 9 truncating mutations arising from insertions, deletions and nonsense stop signals. 
Five missense mutations occur in exon 1. Th.:.se include a G-). T transition at nucleotide 
position 3, which changes the initiating AUG codon to AW, causing a methionine to 
isoleucine substitution (Kolosha et al., 2000). This causes translation to begin at the second 
AUG codon resulting in a galactokinase protein lacking the first 54 annino acids. The 
second missense mutation in ex on 1 is a 82C~ A transversion causing a proline to 
threonine amino·acid change at codon 28. This substitution was identified as the founder 
mutation causing galactokinase deficiency within the Vlax Roma population (Kalaydjieva et 
al., 1999). This missense substitution occurs in close proximity to a 94G~A transition that 
results in a V32M change, reported in an unrelated sample (Stambolian et a!., 1995). 
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Table 2.4 
Mutations Identified in GA LKJ 
Mubtion type Nucleotide Amino acid Result 
St:unbolian et ..!. (1995) Missense 94A~G V32M Disrupts loop-beta tum motif 
Nonsense 238G--.T QBOX Stop codon ...... truncated protein 
Kab.ydjieva et al. (1999) Missense 82C--.A P28T Disrupts loop-beta tum motif 
Asada et ..!. (1999) Missense 766C--.T R256W Not characterized 
Missense 1031C-+G T344M Occurs at A TP binding site II 
Missense 1045G---ioA G349S Occurs at A TP binding site II 
Deletion 410deiG 163 In frame nonsense codon 
Deletion 509-SlOdeiGT 201 In frame nonsense codon 
Kolosha et ..!. (2000) Insertion 228ins 67bp 77 Frameshift at amino acid 77 
Missense 3G-+T Mll Protein lacks first 54 amino acids 
Insertion 1012insG 338 Frameshift at amino acid 338 
Nonsense 1144C--->T Q382X Stop codon--. truncated protein 
Ddetion 761deiG 254 Frameshift at amino acid 254 
Missense 106G--->C G36R Occurs near conserved region 
Insertion 610insG 204 Stop codon-.. truncated protein 
Missense llOC--->T H44Y Occurs near conserved region 
Missense 1036G-+A G346S Occurs at ATP binding site II 
Insertion 280insACT= 94 Frameshift at amino acid 94 
Two other missense mutations occur in exon 1 and include a 106G~C transversion 
causing a G36R substitution, while the other is a 130C4> T transition resulting in a H44Y 
amino acid change {Kolosha et al., 2000). Three missense mutations, R256W, T344M and 
G348S (Asada et al., 1999) occur at CpG nucleotides, which are known mutational hotspots 
(Cooper et al., 1995). One of these, R256W caused by a 766C~T transition, is found in 
exon 5 (Asada et al., 1999). This mutation does not occur within a recognized conserved 
motif and its effects upon the structure of the protein were not investigated. Both the 
1031C~G transversion which prtxhces the T344M amino acid change and tbe 1045G~A 
transition which causes the G349S substitution, occur in the ATP-binding site sequence in 
exon 7. An additional missense mutation has also been found to occur in this region and is 
a G346S substitution resulting from a 1036G~A base change {Kolosha et al., 2000). 
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A nwnber of truncating mutations have also been reported in the GALKJ gene. Two 
of these, ESOX and Q382X, are the result of nucleotide changes. ESOX results from a 
238G~ T transversion in exon 2, which creates a termination codon producing a truncated 
galactokinase protein of only 79 amino acids (Starnbolian ct al., 1995). The Q382X 
nonsense mutation results from a 1144C-1> T transition in exon 8, which is known to 
encode the carboxyl terminus of the enzyme. As a result of this premature termination 
codon, the enzyme was predirted to lack a number of C-terminal amino acids. Subsequent 
expression analysis in oocytes suggested that low measured galartokinase activity was 
attributed to the 1144C-> T substitution. This finding suggests that the carboxyterminus of 
the protein is essential for normal galactokinase function. 
The remaining truncating mutat1.ons result from 3 deletions, 4lodelC, 509-SlOdelGT, 
(Asada et al., 1999) and 761deiG (Kolosha et al., 2000) and 3 insettions, 610insG, 
280insACfGCCC and 1012insG (Kolosha et al., 2000). All result in frarneshifts that 
produce a truncated protein. The duplication of a 67bp sequence of the 5' end of exon 2 
and 5bps of the adjoining intron (288ins67bp) found in one individual was found to cause 
an additional 5' splice acceptor site (K.olosha et al., 2000). This insertion results in the 
removal of the normal 5' end of exon 2 during splicing, producing a partial and thus 
nonfunctional galactokinase transcript. 
Mutations characterized within the GALI\1 gene have pointed towards the functional 
significance that particular regions may have upon the encoded protein. The clustering of 
nucleotide aberrations within highly conserved areas of the GALI\1 gene or recognized 
functional motifs, highlight the impottance that each region has in the normal activity of the 
encoded galactokinase. Five missense mutations, Mil, P28T, V32M, G36R and H44Y 
occur in exon I and of these, both G36R and H44Y reside within the highly conserved 
galaaokinase signature domain. Their effects upon the secondary structure of the protein 
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are not reponed, however it is likely that they interfere with an unknown function that 
seems critical for normal galactokinase activity. The two missense mutations, P28T and 
V32M, occur in close proximity to this signature sequence. In fact, computer models of the 
protein configuration c~used by both P28T and V32M, reveal similar secondary structural 
changes that interfere with a loop-beta tum motif immediately preceding the conserved 
domain (Kalaydjieva et al., 1999). The fact that the majority of the missense mutations 
found in the GALl(] gene cluster within exon I, which encodes the highly conserved 
fingerprint motif, suggest this region plays a crucial role in the normal activity of the 
enzyme. 
Another clustering of three missense mutations and one insenion occurs in the 
second A1P-binding motif in exon 7. Three of these, T344M, G346 and G349S, occur 
within a 5 codon span, suggesting a small region exists within this domain that is critic.U for 
nonnal function. The fact that these are missense mutations, may reflect a critical 
conformational dependence in order for normal A TP binding to occur in the encoded 
protein. 
To-date, only three mutations (P28T, Q382X and G349S) have been reported to 
occur in multiple individuals with galactokinase deficiency. The G349S substitution has 
been found in the heterozygous state in two galactokinase-deficient individuals. These 
patients differ in ethnic origin: one is German (Kolosha et al., 2000) and the other Japanese 
(Asada et al., 1999}, suggesting this mutation is a reccurence of the amino acid substitution 
at the same codon. The remaining two mutations, P28T and Q382X appear to be founder 
mutations. Although the common origin of P28T has been confirmed by haplotype analysis 
in six Gypsy families from Bulgaria (Kalaydjieva et al., 1999), it is unclear whether the same 
mutation accounts for all affected individuals among the European Gypsies. No haplotype 
analysis has been conducted among the Costa Rican/Europeans with Q382X, therefore a 
founder effect can only be assumed. 
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2.6 Summary 
Clearly, the lack of conclusive data about both the functional and structural 
characteristics of the CALK! gene, as well as the influence of age, tissue specificity and 
allelic variation upon the encoded enzyme product, allows only a limited insight to the 
complete process of galactose metabolism. One way towards understanding this process is 
futther analysis of the CALK/ gene. Any mutations found during such investigations will 
help the progression towards a complete characterization of the galactokinase gene and 
galactose metabolism. Furthermore, the lack of conclusive information regarding the 
frequency and distribution of common mutations in the GALKJ gene needs to be 
addressed to allow further research into genotype/phenotype correlations. Not only will 
this aid in the development of newborn screening strategies in high risk groups and 
prevention of infantile blindness, but will also allow the link between partial deficiency and 
presenile cataract development to be fully investigated. 
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CHAPTER 3 IDENTIFICATION OF GALK/ MUTATIONS IN PATIENTS 
WITH GAIACTOKINASE DEFICIENCY 
3.1 SUBJECTS 
Patients included 9 individuals with galactokinase deficiency. Most had been detected 
as hypergalactosemic by newborn screening (fable 3.1). The exception was a Gypsy child 
from Bulgaria, who had undergone surgery for infantile cataracts. The patients are on 
galactoseMrestricted diet and are symptom-free. Galactokinase deficiency (< 5% of the 
lower limit of the normal range} was confirmed by enzyme activity measurements in red 
blood cells (RBC). All patients have normal galactose-1-phosphate uridyl transferase and 
UDP-epimerase RBC activity. 
Table3.1 
Biochemical Findin~s of Study Sample 
Patient Hypergalactosemia Galactosuria Galactokinase 
!• + + Deficient 
2' + + Deficient 
)• + + Deficient 
4' + + Deficient 
5• + + Deficient 
6d + + Deficient 
7d + + Deficient 
Sd + + Deficient 
9• + + Deficient 
• Dept of Pediatrics, Harvard University Medical School, Boston, USA 
b Univenity Ollldren 's Hospital, Zurich, Switzerland 
c Institut Bioquimica dini.ca, Barcelona, Spain 
d Dept. of Pediatrics, Medical School, Szeged, Hungary 
e Bulgaria 
RBCAttivi 
G·l·P 
uridyl transferase 
Nonnal 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
UDP· 
ep1merase 
Normal 
Nonnal 
Normal 
Nonnal 
Nonna1 
Nonnal 
Normal 
Normal 
Normal 
Origin 
European/ America 
Twlillh 
European/ America 
Spanish Gypsy 
Spanish Gypsy 
Hungarian Gypsy 
Hungarian Gypsy 
Hungarian Gypsy 
Bulgruian Gypsy 
The DNA samples of these patients have been provided for analysis by the Genetic 
Service, Children's Hospital and Department of Pediatrics, Harvard Medical School, 
Boston, USA, the University Children's Hospital, Zurich, Switzerland, the Institut 
Bioquimica Clinica, Barcelona, Spain and the Depanment of Pediatrics, Medical School, 
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')zeged, Hungary. DNA from three individuals without galactokinase deficiency were used 
o1s controls and were sequenced in parallel with patient DNA. These samples were chosen 
from a DNA bank maintained within the Centre for Hwnan Genetics at Edith Cowan 
University. 
Consent for DNA analysis was obtained from the parents of all participants in the 
study. The investigation complies with the guidelines of the Edith Cowan University Ethics 
Committee. 
30 
3.2METHODS 
3.2.1 Experimental Design 
The strategy used in the current investigation included: 
a} Detection of mutations: - by sequence analysis of the entire CALK! coding region, 
flanking intronic sequences and both the 5' and 3' UTR. 
by direct testing of the P28T mutation in individuals of 
Gypsy ethnicity. 
b) Independent confirmation of identified variants using other methods of mutation 
detection: 
c) Computer analysis: 
3.2.2 DNA Q~tantification 
confirmatory analysis of the original DNA sample using an 
independent PCR amplification and a different method. 
screening a panel of 50 Caucasian controls (100 chromosomes). 
comparisons of sequences. 
analysis of the nature of the sequence variants. 
predicted effects on protein structure/function. 
The concentration of the provided DNA samples was detennined using a Beckman 
ou• 640 UV spectrophotometer. This is achieved by reading the absorbance of a DNA 
sample in d.H20 c:t a wavelength of 260nrn. Concentration of each sample can be calculated 
using the fact that one optical density unit at this wavelength equates to SO~g/ml of DNA 
(Sambrook, Fritsch, & Maniatis, 1989). The ratio between the readings at 260nm (DNA) 
and 280run (phenolic rings) provides an estimate of the purity of the nucleic acid. Knowing 
the starting concentration of each of the DNA samples allows the accurate dilution to a 
suitable working solution. For the purposes of this study, a concentration of 20ng/11l of 
DNA was employed. 
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3.2.3 PCR Amplificatio" 
Amplification of GALKJ was perfonned using the polymerase chain reaction (PCR). 
This procedure has revolutionized molecular investigations of the genome, allowing great 
specificity and ease in obtaining a large number of copies of template DNA from even the 
smallest concentration of starting material. A standard PCR reaction involves the addition 
of a heat-stable DNA polymerase, dNTPs, sequence specific primers, buffer, dH20 and 
MgCl2, to a sample of DNA Successive temperature cycling causes denaturing of DNA to 
single-stranded templates, then a period of cooling to allow the annealing of 
oligonucleotide primers, followed by another temperature change that allows activation of 
the polymerase. The activated polymerase catalyses synthesis of new DNA strands, utilizing 
the provided d.NTPs in the reaction. With continued cycling, an exponential increase in 
DNA templates is achieved. A number of parameters may influence the yield of the desired 
target product and can be adjusted accordingly to obtain optimal amplification. Some of 
these include concentration, quality and the sequence of starting DNA, reagents, cycling 
times, temperature and the addition of solvents such as DMSO for fragments with high 
denaturation temperatures. 
Primers previously used for PCR amplification of GALKI were utili:red for obtaining 
the sequence of the coding regions of the gene and at least 100 bp of flanking intronic 
sequences (Table 3.2). Primers for the entire S'UIR were designed from the published 
GALKI sequence (Genbank Accession ' L76927). Due to suspected errors in the 
published 3'UTR sequence, primers for this region were selected from the Homo sapiens 
chromo.<ome 17 clone RP!l-4741111 (Genbank Accession' AC019214). Optimal cycling 
conditions and parameters were determined for each fragment using a series of MgCl2 
titrations (1mM, 1.3mM, 2mM & 2.5mM) and DMSO concentrations (1-5%) and run upon 
a PTC-200 gradient thennal cycler (MJ Research Inc.). PCR amplification of DNA 
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Table 3.2 
PCR Primer _Sequences and Conditions for GALJ(l 
GAl.K1 Nucleotide PCR 
Rc ·on Primer sequencea positionb Conditions Additives Notes 
5'UTR (F) 5'-CI'GATGA=CTCACAGCfGC-3' 1-21 SS"C for 35 cycles 1.5 mMMgC!, 
5UI'R(R) 5'-CGAAGTcx:AGAGGGAAGGAC3' 224-243 
5UI'R (F) 5'-CI'ATTCTCACTCTAGTGAGTGC-3' 188-209 63"C for 35 cycles 1.5 MgCI, 
5UI'R (R) 5'-CGTCATGGCfGCTTTGAGACAG-3' 473-499 
I (F) 5'-=GAGCAT=GCCGAC3' 419-438 63"C for 35 cycles 4% DMSO, 1.25mM MgCI, 
1 (R) 5'-GACAGGCfGTT=::cACGT-3' 800-818 
2(F) 5'-ACTGTGGAGGCATCAGAAC:C3' 1436-1455 TD 63'C->56"C 4% DMSO, 1.5mM MgCI,, Jv1anual hotstan 
2 (R) 5'-CACAGAGCcx:ATTCATTTGTCTGA-3' 1781-1805 
3(F) 5'-CCTAGAAACAGTTGCfAGGC-3' 2071-2090 TD 63"C-+55"C 4% DMSO, l.SmM MgCb 
3 (R) 5'-GTGGTox:AGCTTCTACTAT-3' 2354-2373 
4(F) 5'-AGTGTCATTGAAGCCACTGC3' 2408-2427 1D 63°C-)-57°C 1.5 mMMgCI, 
4 (R) 5'-CAAGCACACGCTTGGCCTCGT-3' 2686-2706 
5(F) 5'-AGCAGCf=GGGTGGAGTGT-3' 2647-2667 TD 63"C-+55"C 4% DMSO, 1.5mM MgC!,, 11anwl hotst.m 
5 (R) 5'-CI'CAGTGTGGCCTTGA=-3' 2971-2990 
6(F) 5'-ATCACCGCCTGCfGGT=C3' 6945-6964 1D 63°C-).55"C 4% DMSO, I.OmM MgC!,, Manual hotstan 
6 (R) 5'-CCCAGGCcx:Acc=TCAATA-3' 7217-7238 
7(F) 5'-CI'CATGGTGGAGAGCCACCG-3' 7146-7165 65"C for 30 cycles 4% m ISO, I.OmM MgC!, M.lilual hotst.m 
7 (R) 5'-CI'CAAGCAGCCGATGGAGCC3' 7530-7549 
8(F) 5'-ACGCCATGCGGCACATcx:AG-3' 7394-7413 1D 63"C-+55"C 4% DMSO, 1.5ffi1.1 Mgd~ 
8 (R) 5'-CI'CTGT=GGTGCCATCTT-3' 7624-7644 
3'UIR (F) 5'-GCTGTGCTTGTGAGGCAC:C3' 7555-7573 63"C for 30 cycles 4% DMSO, 1.5mM MgCI, 
3'UIR(R) 5'-CTTCCAAACTTGACCGCA=·3' 8059-8081 
• Adapted from Kalaydjieva et al (1959) 
b Nucleotide nwnbering based upon Genbank accession#L76927 
~ 
~ 
according to the optimized conJitions was carried out in 501-11 reactions. The conditions arc 
detailed in To~ble 3.2. Both the 96 well PTC-100~ Programmable Thennal Cycler {MJ 
Research Inc.) .md the Gcneamp PCR systc·m 2400 (Applied Biosystems) were used for 
PCR cycling. 
To check the successful amplification of each genomic target, all PC:R products were 
size-sepo1rated by gel electrophoresis. 2.5% agarose milligels were prepared by adding 2.5 
grams of DNA grade agarose powder to lOOmis of IxTAE buffer. The solution was heated 
in a microwave oven until agarose had dissolved, and placed in a dry incubator to cool to 
60 degrees C. Prior to pouring, 3.51-11 of ethidium bromide was added to each agarose 
solution to allow lN visualization of PCR products. The agarose solution was poured into 
Perspex casting trays to a depth of approximately Smm, well combs were insened and the 
gel allowed to set at room temperature under a fumehood for 30 minutes before use. 
Combs were then removed and the gel was placed into an electrophoresis tank (Biorad 
Mini-Sub • Cell GT), !xTAE buffer was added to cover the gel to a depth of approximately 
2-3mm. 5~1 of each PCR product were mixed with 1~1 of loading buffer (0.25% bromo 
blue, 0.25% xylene cyanole, 15% ficoll) and loaded into single lanes of the gel. A 1~1 aliquot 
of pUC!9/Hpa II (PE Biosystems) DNA molecular marker was loaded into the left-hand 
side of each gel co give an indication as to the size of each PCR product. The 
pUC!9/Hpall ladder gives a series of bands of known nucleotide length ranging from 26 
to SO! bps. This allows a visual size estimation of the PCR product to be obtained and 
compared with the expected fragment length. Each gel underwent electrophoresis at 80V 
for approximately 30 minutes and was then removed from thr electrophoresis tank and 
visualized on a Hoefer Mighty BrightTll UV Illuminator. Images were recorded using a 
Kodak" DC120 digital camera and Kodak" Digital Science~ software. 
After confirming sufficient amplification, PCR products were cleaned of 
unincorporated dNTPs, primer dimers and amplification primers, using the QIAquick 
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purification kit (QIAGEN, Austr.tlia). This entailed the addition of 5 volumes of PB buffer 
to e.tch PCR product. Each sample was inverted to mix, then pipcttcd into a separate 
QIAquick spir1 colwnn. DNA WolS bound to the QIAquick membrane by centrifugation at 
15 000 rpm for 1 minute in an Eppcndorf 54 17c centrifuge. The flow~through was 
discarded before the addition of 7501-11 of PE wash buffer and further centrifugation at 15 
000 rpm for l minute. The flow-through from this step was discarded and an additional 
spin under the same conditions was performed to remove any residual PE buffer. Columns 
were then placed into sterile, labeled l.Sml Eppendorf tubes and the bound PCR product 
eluted with the addition of 30~1 of dH,O and a final spin at IS 000 rpm for I minute. 
Eluted DNA was then stored at -20 degrees C until further analysis. 
3.2.4 Big Dye Terminator Cycle Sequencing 
Clean PCR products were sequenced using the ABI PrismTll Big Dye Tenninator 
Cycle Sequencing Ready Reaction Kit. This procedure invoives the incorporation of a 
fluorescent-labeled dideoxynucleotide at the 3' end of DNA strands. The 
dideoxynucleotide prevents further elongation of the template DNA and as its addition is 
mediated by competition with its corresponding unlabelled dNTP added to the same 
reaction, a series of fragments of different sizes are produced. 
Each reaction was prepared on ice and consisted of 1-2~1 of target DNA (20ng/~l), 
4~1 of BigDye Terminator, 1~1 of forward or reverse primer (20ng/~l) (Table 3.2) and 
dH,O to a final volume of 10~1. Reactions were then placed in a 96 well PTC-100~ 
Programmable Thermal Cycler (MJ Research Inc.) under the following cycling parameters: 
rapid thermal ramp to 96 degrees C, held at this temperature for 10 seconds, a rapid 
thermal ramp down to 50 degrees C helci for 5 seconds. This was followed by rapid 
ramping to 60 degrees C and held for 4 minutes. This cycling was repeated 24 mere times. 
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3.2.5 Ethanol/Sodi~tm Precipitation 
Sequencing reactions were cleaned using a precipitation reaction designed to remove 
excess nucleotides and primers that would otherwise interfere with the accuracy of the 
sequence signal. This entailed the addition of 1~1 of 3M sodium acetate (pH 4.6) and 25~1 
of 95% ethanol to each sequencing reaction. Tubes were inverted to mix, then left at room 
temperature for 15 minutes to allow the precipitation of extension products before 
centrifugation at 3000 x g for 30 minutes in a Hermie Z823 centrifuge. Open tubes were 
then inverted on a tissue folded to fit the size of the carry tray and then spun at 700 x g for 
1 minute to remove any residual ethanol. 75~1 of 70% EtOH was then added to each tube 
and again tubes were inverted to mix before centrifugation at maximum speed for 10 
minutes. Open tubes were then placed upside down on a clean folded tissue and spun at 
700 x g for an additional minute before being left to air dl)' for approximately 10 minutes 
to ensure complete evaporation of residual ethanol. 
3.2.6 Sequencing Gel Preparation 
Sequencing gels were prepared by adding 5 ml of filtered 10XTBE to 18g of urea in a 
SOrnL glass graduated cylinder. 4.75mL of LongRanger Gel solution was added to this mix 
before the addition of dH,O to a final volume of 45rnL. The top of the cylinder was 
covered with paraftlm and inverted to dissolve the remaining urea. The final volume was 
brought to SOml with dH,O. The solution was filtered using 0.2~m filter paper before 
degassing for 10 minutes in a vacuum. Prior to pouring the gel, 250~1 of 10% APS 
(anunonium persulphate) and 35~1 of TEMED (N',N ,N',N'-tetra-methylethylenediarnine) 
were added. The solution was poured using a 50 ml syringe, the loading inserted and the gel 
assembly clamped. The gel was left to set for approximately 2 hours before fitting to an 
ABI Prism~ 377 DNA Analyzer. 
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3.2.7 Electrophoretic Conditions 
Priorto loading, 4~1 of a 5:1 EDTA (SOmM) + Blue dextran (SOmg/ml)i Formamide 
loading solution were added to each precipitated reaction pellet. The reactions were 
denatured for 3 minutes at 94 degrees C. Products were then snap-chilled on ice to ensure 
they remained in a single-stranded conformation. l1-1l of each sequencing reaction were 
pipetted into alternate single lanes of the gel, pre-warmed to 51 degrees C. Samples were 
run for 2 minutes before sequencer was paused and the remaining samples loaded in 
adjacent empty lanes. The electrophoresis was run for 11 hours at 2400V. Sequencing data 
were downloaded to an iMAC-Macintosh computer and analyzed using the Sequence 
Navigator~ (PE Biosytems) software. 
3.2.8 Web-Based Databases Utilized in the GALKl Analysis 
A number of web-based genomic and protein databases and tools have been 
developed to cope with the increasing amount of sequence data being deposited in the 
public domain. A nwnber of these were utilized in the rurrent investigation. 
3.2.8.1 Nuclrotide and prot£inSffJUD1CES 
The nucleotide and the amino-acid sequences of the Homo sapiens GALKJ gene 
and galactokinase protein were obtained from the National Centre for Biological 
Information (NCBQ available at [http:! /www.ncbi.nlm.nih.gov]. Genbank accession 
numbers L76927, AF084935 and U26401 were utilized for nucleotide comparisons. 
Protein sequence and codon numbering were derived from Genbank Accession ~ 
PS00106. 
3.2.8.2 Residuelxmdctgy 
The BLAST alignment program, available at [http:/ /www.ncbi.nlm.nih.gov/BLAST/], 
was utilized to establish whether mutations ocrurred at evolutionary conserved 
residues. It is assumed that conserved residues are under positive selection and are 
thus maintained across species due to their functional significance for the encoded 
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protein. The BLASTP alignment compares characterized protein sequences deposited 
in the public databases to a query sequence. In this study the human galactokinase 
protein sequence was compared with the galactokinase protein sequences of 
approximately 20 organisms. 
3. 2. 8.3 Restriaim endm:clmse selroWn 
The WebCuner program available at [hnp://www.firstmarket.com/cuner/cut2.html] 
was used to determine whether the detected nucleotide changes produced or 
abolished restriction endonuclease recognition sites. The WebCutter software utilizes 
a database called REBASE available at [http://www.rebase.neb.com]. The database 
is a compilation of characterized restriction endonucleases and associated recognition 
sites that is updated on a regular basis (Roberts & Macelis, 2000). 
3.2.8. 4 Motif dete:Iim <1T7d ali1!J1117mt 
The web-based motif alignment tool SPRINT, available at 
[http:/ /www.bioinf.man.ac.uk/dbbrowser/sprint/], was used to calculate and 
identify significant regions of homology between the human galactokinase protein 
and the sequences of galactokinase proteins from other organisms. The purpose of 
the motif alignments is to compare known or similar motifs in other proteins 
deposited in the public databases and obtain an indication as to the function of a 
protein or the family to which a protein sequence belongs. 
3.2.8. 5 Seandttry St:rudural Prrrlicticn 
Computer modeling of the predicted structure of the mutant protein was done with 
the PHDsec algorithm (Rost & Sander, 1994) available at 
[http:// dodo.cpmc.columbia.edu/ predictprotein/ submit_ def.html]. This algorithm 
calculates the conformational probability that a specific residue will result in the 
formation of a helix, loop or extended beta-sheet in the second:uy folding of the 
protem. 
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3.2.9 Mutation Detection Techniques 
Nucleotide changes were also independently detected on a second PCR product 
derived from genomic DNA of each patient by using various mutation identification 
methods, including restriction endonuclease assays, single strand conformational 
polymorphism (SSCP) and heteroduplex analysis (HDA). The principles and methods for 
each of these techniques are described below. 
3.2. 9.1 RestrictWn Endmudease Assays 
Nucleotide changes were detected using restriction endonucleases. Isolated from 
prokaryotic organisms, these enzymes cut DNA at specific recognition sites. Their 
natural function is to remove foreign DNA sequences from the host genome. They 
also provide a useful tool for mutation detection if the nucleotide change in question 
abolishes or creates a recognition site differing from the wild-type sequence. Four 
restriction enzymes were utilized in the current analysis: N1aiii (New England 
Biolabs cat' R012SS), AlwNI (New England Biolabs cat' ROS14S), Bbvl (New 
England Biolabs cat' R0173S) and Ava! (New England Biolabs cat' R0152S). For 
the Bbvl assay, 10~1 of product {"100ng/~l) was digested with 1~1 of enzyme (2 
units/~!), 2~1 of 1x NE buffer and 7~1 of dH,O in a final reaction volume of 20~1. 
The protocol for the Ava!, Nlalll and AlwNI assays differed by the addition of 2~1 
of 1 x BSA (bovine serum albumen). All digests were incubated at 37 degrees C for 
2hours. Products from the Ava!, Bbvl and Nlaiii digest were then run upon a 4% 
agarose/EtBr gel at 60V for 1 hour and visualized on a Hoefer Mighty Bright m UV 
Illuminator and the image was recorded using a Kodak• DC120 digital camera and 
Kodak• Digital Sciencenl software. The AlwNI digest products were run on 12% 
PAG gels in 1 X TBE buffer for 1 hour at 200V. Gels were then silver stained 
according to the protocol in Section 3.2.9.2 
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3.2.9.2 SSCP and HDA M11tatim Deta:tim 
Single~strand conformation polymorphism (SSCP) is a mutar.ion detection technique 
which relies on the fact that single base changes and deletions may cause changes to 
the primary folding of each DNA strand resulting in aberrant electrophoretic 
patterns {Orita, Suzuki, Sekiya, & Hayashi, 1989). 
Heteroduplcx {HD) analysis involves the detection of similar shifts in mobility of 
mismatched duplexes of DNA strands, caused by single base substitutions and 
particularly insertions and deletions (White, Carvalho, O'brien, & Dean, 1992) 
SSCP analysis involves denaturation of a double-stranded PCR product with 
formamide and heat and are snap·chilled on ice before electrophoresis on a 
nondenaturing polyacrylamide gel. For HD analysis, PCR products are denatured 
without formamide and are allowed to cool slowly so as to form both matched 
(homoduplex) and mismatched {heteroduplex) DNA duplexes before 
electrophoresis. 
For both SSCP and HD analysis, a 140 bp product of exon 5 was amplified using 
forward primer 5'-CCAGGTCCITGGAGACCAGC-3' and reverse primer 5'-
CAi\.GGAAAGCCfC:CGGGAGG-3'. Cycling conditions for this fragment included 
initial denaturation at 94 degrees C for 5 minutes, followed by 16 cycles using ' 
touch-down regime of denaturing at 94 degrees C for 30 sec, annealing from 63 
degrees C to 55 degrees C {0.5 degrees C increments) for 30 sec and extension at 72 
degrees C for 30 sec. This was followed by 20 cycles of 94 degrees C for 30 sec, 55 
degrees C for 30 sec and 72 degrees C for 30 sec before final extension at 72 degrees 
C for 7 minutes. 
PCR products for SSCP analysis were prepared by adding 2~1 of formamide 
loading buffer {98% formamide, 0.025% xylene cyanol & 0.025% bromophenol blue) 
and 2~1 of dH,O to 2~1 of each PCR reaction. Samples were denatured for 3 minutes 
40 
at 94 degrec::s C before being snap·chilled on ice prior to loading. Heteroduplcxes 
were gencrJ.tcd by independently amplifying the same exonic fragment and then 
subjecting 3~1 of PCR product to post-amplification denaturation for 3 minutes at 94 
degrees C. Samples were then allowed to cool to room temperature over a two hour 
duration. Prior to loading, 3~1 of ficollloading buffer was added to each tube. 
Products were run on 12% PAG (29:1 bis-acrylamidc) non·denaturing gels in a 
ice-cooled buffer consisting of 1 x TBE and 5% glycerol. Electrophoresis was canied 
out in a Mini-Protean • Cell II tank (Biorad) at 200V for 2hrs. 
Gels were stained using a silver staining technique, which offers a higher degree 
of sensitivity than ethidium bromide in detecting and visualising DNA on thin gels. 
After electrophoresis, gels were soaked in 10% ethanol solution and gently agitated 
for 3 minutes. This solution was drained, and sufficient 1% nitric acid was added to 
cover the gel(s). Again, gels were left to soak for 3 minutes before the solution was 
drained and three washes with dH,O were performed. Gels were then soaked under 
gentle agitation in 0.1% silver nitrate solution for 10 minutes in a light-protected tray. 
The solution was discarded and gels were washed three times in dH20. A solution 
made up of 25g of sodium carbonate dissolved in 250m! of dH,O plus 300~1 of 
formaldehyde was used to develop the DNA bands. Gels were soaked for 
approximately 1 minute until the solution changed colour. The developing solution 
was then drained and a fresh measure was added. The gels were left to soak under 
gentle agitation until the bands were seen. The remaining solution was discarded and 
the developed gels were rinsed three times in dH20 before fixation in a 10% acetic 
acid solution for 10 minutes. A final rinse with dH,O was followed by a 10 minute 
soak in 1% glycerol to prevent cracking of the gel during the dtying process. Gels 
were placed between two drying film sheets and clamped within a Promega gel 
drying rack and left in the fumehood to dry overnight. Dried gels were photographed 
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on a light box using a Kodak' DC!20 digital camera and Kodak' Digital Science~ 
software. 
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3.3 RESULTS 
Analysis of the CALK! gene m nine patients detected one previously identified 
disease-causing mutation and 4 novel mutations that are likely to cause the galactokinase 
deficiency phenotype (Table 3.3). 
Table 3.3 
GALKJ Mutations in Patients with Galactolcinase Deficieng::. 
Patient RBCGK Nucleotide Amino add change Exo Genotype Ethnic 
activity changea Orip:in 
I Deficient 1569 C-tT R68C 2 Heterozygous European/ American 
753SG~C A384P 8 Heterozn;ous 
2 Deficient 7093C~T T288M 6 Heterozygous European/ American 
2833ddC Frameshift after Y236 5 Heterozygous 
3 Deficient 563C->A P28T I Homozygous Turl<ish 
4 Deficient 563C->A P28T I Homozygous Sp""'h Gyp')' 
5 Deficient 563C-)A P28T I Homozygous Spanish Gypsy 
6 Deficient 563C--'~>A P28T I Homozygous Hungarian Gypsy 
7 Deficient 563C->A P28T I Homozygous Hungarian Gyp5)' 
8 Deficient 563C--:~-A P28T I Homozygous Hungarian Gypsy 
9 Deficient 563C->A P28T I Homozygous Bulgarian Gypsy 
• Nucleotide numbering according Genbank Accession' 176927. 
33.1 Patient 1 
Patient 1 is a compound heterozygote for two nucleotide changes that result in the 
novel missense mutations, R68C and A384P. 
R68C 
Sequence analysis revealed a 1569C--> T transition in exon 2 (Figure 3.1). The 
1569C-+T transition is predicted to result in the replacement of arginine by cysteine at 
codon 68 (Figure 3.2). The arginine residue at this position is strictly conserved in the 
galactokinase protein of over twenty different species checked, including the mouse. The 
mutation is a drastic change from a charged to an uncharged amino acid residue with a 
sulfhydryl side-chain (Figure 3.3), however the computer predictions did not suggest 
significant alterations in tl-te secondary structure of the mutant protein (Figure 3.4). 
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GG C A G C CCC NG C A G A T G G G 
G C C t\ G C C C C C c; C: ,\ ,\ c; c; ,\ T G G G 
T 
(Gcnbank 1\cccs~ion u 1.76927) 
Figure 3.1 1569C~T transition in GALK1 exon 2 causing R68C 
Wild type 
Codon 65 66 67 68 69 70 71 72 
Amino acid G s ~ R K D G L 
N ucleotide GGC "\GC CCC CGC r\AG GAT GGG CTG 
R68C 
Codon 65 66 67 68 69 70 71 72 
Amino acid G s p c K D G L 
Nucleotide GGC AGC CCC TGC AAG GAT GGG CTG 
Figure 3.2 Residue change at codon 68 caused by the 1569C~T transition in exon 2. 
Arginine is replaced with cysteine. 
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Figure 3.3 R68C - molecular comparisons between the arginine and cysteine residues . 
... 
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AlwNI recognition sequence CAGN/ CIG 
Restriction map 
t\lwN I t\lwN I 
Wildtypc ----•-------+!1'1'1"'-------369 bp 
1569C-t'J' 
Expected banding pattern 
_t88 
-95 
- 93 
wilu type 
,\JwNI AlwN I 
'XI/ 'JS 127 
t\lwN I 
lHH 
-95 
- 93 
- 32 
1569C:- fJ' 
heterozygote 
Lane 1 2 3 4 5 6 7 8 9 10 11 12 
-. 
-
-
-- ------ -
-
--- ----
-
369bp 
Figure 3.5 AlwNI restriction digest detecting 1569C~T transition in exon 2 on silver-
stained 12% PAG. Lane 1: Undigested exon 2 patient 1. Lane 2: pUC1 9/Hpaii Ladder. 
Lane 3,4, 6-12: Unaffected. Lane 5: Patient 1 digest. 
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The highly conserved nature of the amino acid residue, as well as the drastic nature of the 
substitution coupled with the fact that the mutation did not occur among control 
chromosomes, suggest that it it is likely that R68C is a clisease-causing mutation. 
A384P 
The second mutation carried by patient 1 is a 7538G~C transversion found in exon 
8 (Figure 3.6). The 7538G~C base change leads to the substitution of proline for alanine 
at position 384 of the galactokinase protein (Figure 3.7). Both alanine and proline are non-
polar amino acids (Figure 3.8). Alanine at this position is not highly conserved, it is present 
onJy in the two mammalian gaJactolcinases characterized so far, human and mouse, and 
sequence similarity is found in the proteins of seven additional species. 
C A 
c " 
A G C A N C C G A T G G A G 
1\ G C A G C C G A T G G A G 
c 
(Genbank Accession II L76927) 
Figure 3.6 7538G~C transversion in GALK1 exon 8 causing A384P. 
Wild type 
Codon 381 382 383 384 385 386 387 388 
Amino acid s Q A A D G A K 
N ucleotide TCT CA"\ GC\ GCC GAT GGA. GCC AAG 
A384P 
Codon 381 382 383 384 385 386 387 388 
Amino acid s Q A p D G A K 
Nucleotide TCT CAA GCA CCC GAT GGA GCC AAG 
Figure 3.7 Residue c~ange at codon 384 caused by the 7538G~C transversion. Wildtype 
alanine is replaced with proline. 
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coo· 
+HJN ___J -+t 
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CH, 
Alanine 
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aliph:~tic 
coo· 
•>;,N--b-H 
I I 
~c, ~c~ 
'c' 
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nonpolar 
cyclic 
Figure 3.8 A384P- molecular comparisons between the alanine and proline residues 
The substitution of proline for alanine is likely to induce significant topological 
changes, as predicted by the secondaty structural analysis. The helix formed between the 
F378 and A384 residues in the wild-type protein is abolished by the mutation, which also 
leads to an extension of the beta sheet and causes loop formation by adjacent residues 
(Figute 3.9). A384P is located 8 amino acid residues upstream of the carboxyl tenninus of 
the protein and is the second reported mutation in exon 8, after Q382X (Kolosha et al., 
2000), suggesting that this part of the protein is essential for galactokinase function. 
Galactokinase exon 8 wild-type 
370 
' 
380 . 
' 
. 390 
M IE H y G G T A T F y L s Q A A D G A K v L c ~I PHDsec H H E E H H H H H H H E E E E SUB~, H H . L L L L L 
Galactokinase A384P 
370 
' 
380 
' 
. 390 
M E H y G G T A T F y L s Q A p D G A K v L c L 
PHDsec H H H E E E E E E E E E E 
SUBsec H H H E E E E E L L L L L 
Figure 3.9 Secondary-structure prediction for the wild-type exon eight galactokinase 
sequence and the A384P missense mutation using the PHDsec algorithm. P384 in 
boldtype face. E - extended sheet (beta sheet); H- helix; L - loop. The prediction is 
meaningful for all residues with an expected average correlation > .69. 
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The 7538G---7C transversion (A384P) abolishes a Bbvl endonuclease restriction site 
marked by the sequence 5' GCAGCNx 3' and 3' CGTCGN 12 5'. To confirm that the 
transversion does not occur in the wild-type population, a Bbv I restriction assay was 
performed on the PCR product encompassing the entire exon 8 sequence from both the 
proband and SO unaffected controls (Figure 3.10). The 7538G---7C transversion was not 
detected among the control samples assayed. 
Bbvl recognition sequence 5' GCAGCN~ 3'and 3' CGTCgN,2 5' 
Restriction map 
Bb\"1 
Wildtypc ____ ..,., ________ ......,111!"'" ____ 250 bp 
7538G-tC: 
Expected banding pattern 
Lane 1 
-109 
86 
--55 
wild type 
.2 
Bb\"1 
56 
3 4 
_ 194 
-109 
86 
--55/56 
7538G-tC: 
heterozygote 
5 
250bp 
6 
Figure 3.10 Bbv I Restriction Digest of Exon 8 PCR Product. Lane 1: pUC19/ Hpa II 
Ladder. Lane 2: Undigested exon 8 of patient 1. Lane 3: patient 1 digest. Lanes 4,5,6: 
Unaffected controls. 
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It is likely that A384P is a disease-causing mutation based upon the fact that it 
induces topological changes in the secondary structure of the protein, resulting from the 
change from an aliphatic (alanine) residue to a cyclic (proline) residue. This is supported by 
failure to detect it among 100 control chromosomes. 
3.3.2 Patient 2 
Patient 2 is heterozygous for a nucleotide transistion in exon 6 and a single base 
deletion occurring in exon 5. The patient was also heterozygous for nucleotide transitions 
in the S'UTR (303A---7G) and intron 2 (2148C---7T). 
T288M 
Sequence analysis detected a C---7T transi tion at nucleotide 7093 (Figure 3.11). The 
7093C---7T transition causes the substitution of methionine for threonine at codon 288 
(Figure 3.12). Although the mutation results in the replacement of a polar amino acid 
residue by a nonpolar with a sulfur-containing side-chain (Figure 3.13), the secondary 
structural predictions are inconclusive (Figure 3.14). 
A TT C GG C G C ANG G C CC AGG C A 
AT'J' C GG C GC A CG GC C C i\GG C i\ 
T 
(Gcnbank Accession # L76927) 
Figure 3.11 7093 C---7T transition in GALK1 exon 6 causing T288M . 
.. . 
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T288M is th~ first mutation identified in cxon 6 of GALKJ and occurs in a region 
identified by the web-based motif alignment tool, SPR!Nf (available 
http:/ /www.bioinf.rnan.ac.uk/dbbrowser/sprint/) as encoding a conserved galactokinasc 
fin~erprint motif sequence. As shown by the sequence alignment of this ga1actokinasc motif 
(Figure 3.15), the threonine residue at position 288 is conserved in nine out of twenty 
galactokinases. The residue at this position in all but one of the remaining galactokinases is 
valine, which does not differ drastically in terms of side~chain structure from threonine. 
Galactokinase motif four Ore an ism 
K R A R H A v s E N Q R T L K Streptomyces lividans 
K R A R II v v T E N Q R v L D Haemophi/us inj/uen:.ae 
K R v R H I L T E N A R T v E F.scherichia coli 
K R v R H I L T E N A R T v E Bacteriophage lambda 
K R v R H v L s E N A R T v E Salmonella ryphimurium 
K R A K H I I s E N Q R v L E Aclinobaci/lus pleuropneumoniae 
Q R A K H v y s E s L R v L K Saccharomyces cerevisiae 
K R A R H A v s E N Q R T L R Lactobacillus helveticus 
Q R A K H v y s E A L R v L K Kluyveromyces lactis 
Q R A K H v y Q E s L R v L E Candida albicans 
E R A L H v y R E s L R v L K Candida parapsifosis 
R R A K H A v y E N H R A I K Bacillus subtilis 
K R A R H v v L E N Q R T L Q Srreprococcus thermophilus 
Q R A K H v y s E s L R v L K Saccharomyces cerevisiae fGAL3) 
R R A R H v v G E I R R T A Q lfomo sapiens 
-R R A R H v v s E I R R T A Q Mus musculus 
K R A R H A v F E N Q R T L K Lactobacillus casei 
K R A Q H v L E E N E R v L K Thermologa neapo/itana 
K F F G y I v R E N A R v L E Pyrococcus lwrikoshii 
R L v R H v v T E D E R..l;: E R S-/i<Wm 
Figure 3.15 Galactokinase fingerprint motif four. Bold highlight showing amino acid 
variation analogous to residue 288 of the human galactokinase protein at which the T288M 
substirution is found. Methionine at this residue is not shared by any of the galactokinases 
that share the fourth galactokinase fingerprint motif. Motif alignment by SPRINT 
(available http:/ /www.bioinf.man.ac.uk/ dbbrowser/ sprint/) 
The 7093C~ T change creates a Nla III endonuclease restriction site by forming 
the recognition sequence CATG/ (Figure 3.16). Exon 6 of the affected proband was 
amplified by PCR using previously described primers and conditions (Table 3.2). The 
mutation was tested in the panel of control individuals using the restriction assay. It was 
not found among 100 normal chromosomes. 
52 
Nlalll recognition sequence CAIG/ 
Restriction map 
Nlalll 
Wildtype 294 bp 
Niall Nlalll 
7093 c~T 147 204 294bp 
Expected banding pattern 
_204 _204 
-147 
- 9o - 9o 
--57 
wild type 7093C~T 
heterozygote 
Lane 1 2 3 4 5 6 7 8 9 10 
-
-
-
- - - - - - - -
-
- - - --- -
Figure 3.16 Nla III Restriction Digest of 7093 C~ T (f288M) in exon 6 PCR Product. 
Lane 1: pUC19/Hpa II Ladder. Lane 2. Undigested exon 6 of proband. Lanes 3-8 & 10: 
Unaffected controls. Lane 9: Patient 2 digest. 
It is likely T288M is a disease-causing mutation based on the drastic nature of the 
substitution, the observation that it occurs within a fingerprint motif sequence at a residue 
that shows a moderate degree of conservation and the failure to detect it among 100 
control chromosomes. 
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2833delC 
A si ngle base-pair deletion, 2833dciC (Figure 3.17), was found in exon 5, where one 
missense and another truncating mutation have been reported previously (Asada et al., 
1999; Kolosha et al. , 2000). The 2833deiC mutation is preclicted to result in a frameshift 
(Figure 3.1 8) and a premature termination signal at codon 263, leading to a protein that is 
130 amino acids shorter than the wild-type enzyme (Figure 3.19). The presence of the 
deletion was independently confirmed by single strand conformational polymorphism 
(SSCP) and heteroduplex (HDA) analysis. The SSCP analysis proved to be a more 
definitive detection technique for the 2833delC deletion as evidenced by the aberrant 
banding patterns differing from the wild-type controls seen in Figure 3.20. 
T GTGC GG CGG CGCCA 
G C G A G T AC C NNNNN C G GGG GG C C C 
GC GA GT AC C C T G TGCG GC GGCGCC 
delC (Genbank Accession H L76927) 
Figure 3.17 2833delC in exon 5 resulting in a shift of the reacling frame at codon 237 
Wild type 
Codon 233 234 235 236 237 238 239 240 
Amino acid s s E y p v R R 
Nucleotide TCC AGC GAG TAC CCT GTG CGG CGG 
2833deiC 
Codon 233 234 235 236 237 238 239 240 
Amino acid s s E y L c G G 
Nucleotide TCC AGC GAG TAC CTG TGC GGC GGC 
Figure 3.18 Frameshift at codon 237 caused by the 2833delC deletion. Wildtype proline is 
replaced by leucine arid novel protein sequence. 
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SLETSLVPLSDPKLA VLilNSNVIU JSL\SSEYPVRRRQCEEV AR.ALGKESLREVQLEELE 
SLETSLVPLSDPKL-\ VLITNSNVIU-ISLASSEYLCGGAN.VKKWPGRWARKASGRYNWKS* 
Figure 3.19 Protein sequence of CALK! cxon 5 wild-type (upper sequence) and novel 
protein sequence Qower sequence) and premature stop signal resulting from the frames hi ft 
caused by 2833dc!C. 
HD:\ SSCP 
Lane 1 2 3 4 5 6 7 8 9 10 
Figure 3.20 Detection of the 2833delC in GALK1 exon 5 by heteroduplex analysis HDA 
and single strand conformational polymorphism SSCP. Products were run on 12% PAG at 
200V for - 2hrs. Lane 1: pUC19/ Hpai marker. Lanes 2,3 & 5: Unaffected controls. Lane 4: 
Patient 2 HDA Lane 6: pUC19/ Hpai marker. Lanes 7, 9 & 10: Unaffected controls. Lane 
8: Patient 2 SSCP. 
Schematic representation of aberrant banding pattern as detected by SSCP 
Wild type 2833de1C 
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Other Nucleotide changes 
Pottiem 2 is heterozygous for a 2148C--).T transition in intron 2. This change is 
located 34 bp upstreoun of the 5' end of cxon 3 and 3 bp upstream of a putative eukaryotic 
consensus branch point sequence, YNRA Y (Rautmann & Breathnach, 1985, Chiara ct al., 
1996). Patient two is also heterozygous for a 303A_,G transition in the SUTR This base 
change occurs within the 250 bp putative cukaryotic polymerase II promoter region 
(Bergsma et al., 1996). As it seems likely that both disease-causing mutations (T288M and 
2833delC) have been identified in the coding sequence of the GALKI gene in this 
individual, it is probable that both 303A->G and 2148C->T, which occur in non-coding 
regions, are not involved in the deficiency phenotype. 
3.3.3 Patients homozygous for the P28T mutation 
3.3.3.1 Patimt 1hrre 
This individual was characterized by sequence analysis and found to be 
homozygous for a 563C---1>A transversion in exon 1, resulting in the previously 
identified missense mutation P28T. 
P28T 
Sequencing revealed a 563C---+ A transversion on both the forward and reverse 
strands of DNA. The mother of this patient is heterozygous for this nucleotide 
change (Figure 3.21). This nucleotide transversion results in the substitution of 
proline for threonine at codon 28 and has been previously shown to induce 
topological changes in the secondary structure of the protein (Kalaydjieva et al., 
1999). The P28T mutation occurs in close proximity to the galactokinase signature 
sequence m exon 1 signaling the importance of this region to normal enzyme 
function. 
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Aval recognition sequence 
Restriction map 
1hal i\\·al 1hal 
Wildtype _______ .,.,""" _____ ..... !"""" ___ """""+""' 400bp 
145 204 ~ 77 
2')4 .177 400bp 
Expected banding pattern 
-294 - 294 
-149/145 .-149/145 
- s3 -s3 3 
___ 23 23 ?3 
wild type 563C~r\ 563C~.A 
heterozygote homozygote 
Lane 1 2 3 4 5 6 7 8 9 10 
Figure 3.22 Ava I restriction endonuclease digest of 563C-7A transversion. Lane 1: 
pUC19/ Hpall marker. Lane 2: Undigested exon product. Lanes 3 & 4: Unaffected 
controls. Lane 5: Mother of patient 3. Lane 6: Patient 3. Lanes 7 & 8: heterozygous 
controls. Lane 9: hompzygous control. Lane 10: negative control. 
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3.3.3.2 Patimts of Gypsy etlmic hackg1uwl 
All six patients, belonging to Gypsy groups geographically dispersed throughout 
Europe (fable 3.3), were homozygous for the 563C->A transversion (P28T) as 
detected by the A val restriction assay. The P28T substitution) previously described as 
a founder mutation, occurs in high frequency in the Vlax Roma Gypsy population in 
Bulgaria (Kalaydjieva et al., 1999). The fact that this mutation is shared amongst 
affected individuals across Europe suggests that P28T may have a more widespread 
distribution 1:han first thought. 
3.3.4 Non~disease causing nucleotide variations 
In addition to the nucleotide changes that were detected in the sample of patients, a 
number of differences from the existing published GALKJ sequence were also identified in 
both affected and unaffectod individuals run in parallel. These are detailed in Table 3.4. 
Table 3.4 
Nucleotide Differences Between Published GALKI Sequences. 
Nucleotide II 
Genbank Accession 
NL76927 
415 
418 
694 
2149 
2151 
2172 
Region 
5UTR 
5UTR 
intron 1 
intron 2 
intron 2 
cxon3 
• Gcnbank accession * U6927 
b Genbank accession ' AF084935 
Nucleotide and Source 
Bergsma ct al. (1996)• Asada ct al. (1999)L 
(n-7) 
C T 
C T 
C T 
C G 
A C 
C ddC 
This study 
(n-9) 
T 
T 
T 
G 
c 
ddC 
The nucleotide changes agree with those reported in a previous study of both affected 
and unaffected Caucasian and Japane'e individuals (Asada et al., 1999). l11is suggests that the 
changes are probably errors in the original sequence (Bergsma et al., 1996) rather than true 
sequence vanants. 
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3.4 DISCUSSION 
The sequence analysis of the enure CALK! coding reg10n, flanking imronic 
sequence and both tht: 5' and 3' UTR in three patients with galactokinase deficienc-y 
revealed 3 novel missense amino acid substitutions {R68C, A384P, T288M) and a single 
base deletion (2833deiC) which are likely to be disease-causing mutations. In addition one 
previously characterized missense mutation {P28T) was also detected. 
3.4.1 Nature of the newly identified mutations 
The R68C substitution in exon 2 occurs at a highly conserved residue that is 
preserved in the galactok.inase protein sequence of a wide number of organisms including 
the mouse, yeast and bacteria. This high degree of evolutionary conservation, coupled with 
the nature of the amino acid substitution, suggests that this mutation is responsible for an 
interruption to normal galacrok.inase activity. As the substitution does not occur in a 
recognized motif sequence, the role that this region of the gene has in the normal activity 
of the enzyme is unclear. R68C is the fourth mutation described in exon 2, the remaining 
three being truncating mutations (Stambolian et al., 1995; Kolosha et al., 2000). 
The A384P change in exon 8 occurs at a residue that is conserved in the murine 
protein sequence and shares a homologous residue among bacteria and yeast. This 
substitution also occurs 2 residues downstream of a previously identified Q382X mutation 
implicated in causing a reduction in galactokinase activity (Kolosha et al., 2000). The dose 
proximity of these mutations signifies that the carboxyterminus of the protein encoded by 
exon 8 pJays an important role in the normal function of the galactokinase protein. It is 
likely that the A384P substitution disrupts this function by inducing topological changes, as 
noted by the secondary structural predictions. 
60 
The fact that R68C and A384P were not detected among 100 norma1 chromosomes 
suggests that these amino-acid substitutions Me the cause of the galat.tokinase deficiency 
phenotype in patient 1. 
The T288M substitution is the first reported mutation to occur in exon 6 of the 
CALK! gene. This amino-acid change is located within the fourth galactokinase fingerprint 
mmif whose function has yet to be characterized. The threonine residue at this position is 
consenred in the galactokinase protein of 7 organisms, including the mouse. The nature of 
the substitution (polar to nonpolar) also suggests that this amino acid change causes a 
reduction of ga1actokinase activity by interfering with a criticaJ function provided by the 
fourth fingerprint sequence. 
The 2833delC deletion m exon 5 would produce a truncated non-functional 
galactokinase protein that is significantly shorter than the wild-type enzyme. When coupled 
with the T288M missense mutation, it is likely that galactokinase activity would be reduced 
to levels conducive to the deficiency phenotype, as is the case in the biochemical 
description of patient 2. The intronic 2149T ~c transition also canied by this patient may 
potentially effect the transcriptional processing of exon three of the CALK! gene by 
interfering with a putative branchpoint motif consensus sequence (Rautmann & 
Breathnach, 1985, Chiara et al., 1996). Similarly the 303A-+G transition found within the 
promoter region of the S'UIR may also affect expression. However without functional 
expression studies both these possibilities are unclear. Evidence will be presented in 
Chapter 4 that these nucleotide changes are not a cause of reduced erythrocyte 
galactokinase activity as the 2149T --+C transversion is shared, in the homozygous state, by 
an individual with nonnal erythrocyte ga1actokinase activity. The same individual is also 
heterozygous for the 303A-+Gtransition. 
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The detection of the previously characterized P28T mutation in patient 3 suggests 
that the incidence of this pmicular mutation may occur in groups other than the Roma 
population. If in fact Patient 3 is of true Turkish extraction as reported, this finding may 
signal the possibility that the P28T mutation may have a more widespread distribution 
across populations in Europe than first thought. Supporting this, was the detection of the 
P28T m1Jtation in eight patients belonging to geographically dispersed Gypsy groups 
throughout Bulgaria, Hungary and Spain. Further analysis as to whether the P28T mutation 
found in these patients is the same founder mutation commOn to the Vlax Roma or reflects 
a recurrence of the substitution at the same codon, forms the basis for the investigation in 
Chapter 5. 
3.4.2 Nucleotide variations 
It is likely that the non~disease associated nucleotide variations from the published 
GALKJ sequence detected in this study reflect errors in the sequence deposited in the 
Genbank database (Genbank accession' L76927). Support lor this claim comes from the 
fact that the same nucleotides were also detected previously among both Caucasian and 
Japanese samples (Asada et al., 1999). The current investigation has detected these base 
changes among European/ American, Afro-Hispanic and Turkish individuals, signaling that 
it is likely that these differences are sequence errors rather than population-specific 
polyrnorphisms. No information as to the ethnic origin of the individuals used in the 
generation of the L76927 GALKI sequence has been provided (Bergsma et a!., 1996). 
Further analysis using a more comprehensive c:ross~section of population groups would 
rebuke or confinn definitively whether these changes are errors or represent true 
polymorphism. 
3.4.3 General discussion of mutation in the GALJ(l gene 
A total of twenty GALKI mutations associated with the galactokinase deficiency 
phenotype have been reported to-date (Stambolian et al., 1995; Asada et a!., 1999; 
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Ko1htydjieva ct al., 1999; Kolosha ct a!., 2000). Except for two founder mutations, namely 
P28T which occurs among the Vlax Roma (Kalaydjieva ct al., 1999) and Q382X found in 
patients of Costa Rican/Europeom descent (Kolosha ct al., 2000), the remaining aberrations 
are private mutations, confined w individual families. Similar to most individuals with 
galactokinase deficiency described previously, two patients in this analysis were also found 
to be compound heterozygotes, adding four novel molecular defects to the allelic 
heterogeneity of CALK! mutations (Figure 3.23). 
The lack of other changes in the coding sequence of the CALK I gene, the nature of 
i.~~~-: dr·r:>r:ted sequence variants and their predicted effect on the protein, lead to the 
suggestion that these arc disease~causing mutations. Including the mutations identified in 
this analysis, the overall distribution to~date is 14 amino acid substitutions and 10 
truncating mutations, with exons 1, 2 and 7 harbouring 13 of the known mutations. The 
majority of missense mutations cluster in close proximity to the galactokinase signature 
sequence in exon 1 and the second A TP~binding domain in exon 7, highlighting the 
functional significance of these regions for the enzyme activity. 
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5'UTR 
Mutation Type 
e Missense 
• Nonsense 
A Insertion 
• Deletion 
Mil 
exon I 
GKJ 
H44Y 
conserved sequence 
• R68C • 2833deiC 
• 410deiG 
228ins67BP 
• E80X 
1 e509-5 1 OdeiGT 
exon 2 
280insACTGCCC 
exon 3 
ATP binding 
motif I 
exon4 
• 761delG 
61 0 insG 
• R256W 
exon 5 
Multiple transcription start sites 
Polymerase II promoter 
0\ 
~ 
Figure 3.23 Distribution of mutations in GALK1. 
exon 6 
T288M 
.&. 1012insG 
• T344M 
exon 7 exon 8 
• A384P 
•Q382X 
3'UTR 
A TP binding Carboxyl 
motif II terminus 
- Conserved/functional regions 
This Study 
Stambolian et al. , (1995) 
Kalaydjieva et al. , (1999) 
Asada et al., ( 1999) 
Kolosha et al., (2000) 
3.4.4 Fttturc Directions 
\Vhile the idcntifical"ion of additional GALKJ mutations m individuals with 
gabctokin.tsc def1ciency should ultimately contribute to understanding the functionally 
important domains of the galactokinase protein, the rarity of the individual defects and the 
compound heterozygous state of most patients, suggest that meaningful studies of 
genotype/phenotype correlations in the affected individuals are not feasible. It is the 
founder mutations, in the homozygous and in the carrier state, that will allow such stucUes, 
as well as research into the role of galactokinase deficiency as a factor predisposing to the 
common presenile cataracts. 
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CHAPTER 4 ANALYSIS OF GAIKl IN PATIENTS WITH THE A TYPICAL 
PHENOTYPE 
4.1 INTRODUCTION 
The CALK! gene was analyzed in two patients sharing a common ethnic 
background (Afro/Hispanic) and presenting with a rare, newly identified phenotype 
characterized by increased blood galactose, lack of production of galactose-1-phosphate, 
but no detectable reduction in erythrocyte galactokinase, galactose-1-phosphate uridyl 
transferase or UDP galactose-4-epimerao;e activity. Due to the role that galactokinase plays 
in the metabolism of galactose, it was considered that the newly identified phenotype may 
result from a defect in the tissue specific expression of CALK!, in particular a liver form of 
the enzyme. Because of the common ethnic background of the patients and the fact that 
they share this rare phenotype, it was hypothesized that a disease-causing mutation in the 
GALKI gene common to both patients, would be present in the homozygous form. 
4.2 SUBJECTS 
The study included two patients, who had been identified by newborn screening as 
hypergalactosemic. The biochemical phenotype of these patients is summarized in Table 
4.1. The two families are unaware of any relatedness, however both ar.~ of Afro-Hispanic 
descent. The aims of the study were explained to the families and infonned consent for 
participation was obtained from the parents according to the ethical guidelines of the 
institutions involved. 
Table 4.1 
Biochemical Findin~s of Study Sample 
RBCActivi 
Patient Hypergalactosernia Gai-1-P Galactokinase G-1-P UDP-
mid~! transferase CE:lmerJ.Sc 
A• + -vo Normal Nonnal Nanna! 
lJo + -ve Nonnal Nonnal Nonnal 
• Dept of Pediatrics, Harvard University School of Medicine 
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4.3METHODS 
DNA was extracted from whole venous blood by the Genetic Service, Children's 
Hospital and Depoutment of Pediatrics, Harvard Medical School, Boston, USA. 
The coding regions of the galactokinase CALK! gene and flanking intronic 
sequences were amplified according to protocols and conditions as described (Chapter 3, 
Table 3.2). PCR primers for the GK1 5' untranslated region (5'UI'R) were designed from 
the published CALK! sequence (Genbank Accession • L76927) as follows: forward primer 
5' -CTGATGACCTCfCACAGCfGC-3' and reverse 5' 
CTGTCTCAAAGCAGCCATCACG-3'. Due to errors in the published GK1 sequence 
(Genbank Accession • L76927), amplification primers for the 3' VIR were chosen from 
the sequence of Homo sapiens chromosome 17 clone RPll-474!111 (AC019214): forward 
5'-GCTGTGCTTGTGAGGCACC-3' and reverse 5'-
CTTCCAAACTTGACCGCAcccr-3'. PCR amplification was performed m a total 
volume of 50 ~1, containing 20% of genomic DNA, 1x PCR Buffer, 1.5mM MgCI2, 
1.25mM dNTPs, 4% DMSO, 2mM of each primer and 0.5 U of Taq. Cycling conditions 
included initial denaturation at 94°C for 5 minutes, followed by 35 cycles of 94°C for 30 
sec, annealing at 63°C for 30 sec and extension at 72°C for 45 sec, and a final extension at 
72°C for 7 minutes. All PCR products were cleaned using Qiagen purification colunms. 
Cycle sequencing of GALKJ was performed using the ABI Prism Big Dye'" 
Terminator Cycle Sequencing Rc~dy Reaction Kit. The products were run on the ABI 
Prism 377 Automated DNA Analyzer. The Sequence Navigator (PE Biosystems) 
software was used for sequence analysis. Patients' sequence data were compared to 
unaffected controls run in parallel and to the published GALK1 sequence. Searches of 
the public domain genomic databases were performed using the BLAST program 
67 
(;waibble http:! /www.ncbi.nlm.nih.gov/BLAST/]. Computer modeling of predicted 
protein structure was done with the PHDsec {Rost & Sander, 1994) software [available 
http:/ I dodo.cpmc.columbia.cdu/ predict protein/ submit_ dcf.html]. 
4.4RESULTS 
4.4.1 Sequerzce analysis of the GALJ(l gene 
Analysis of the entire coding sequence, flanking intronic sequences and the 5' and 3' 
untranslated regions of the two patients identified five nucleotide substitutions differing 
from the wild-type GALKJ sequence. These changes are shown in Table 4.2. 
Table 4.2 
GALK1 Nucleotide Differences in Atypical Patients 
Nucleotide• Location Genotype 
Patient A 303A--_.G 5' UIR Heterozygous 
2149T->C Intron 2 Homozygous 
7087G___.A Exon6 Heterozygous 
7456C4-T lntron 7 Heterozygous 
Patient B 1556G->A Exon2 Heterozygous 
• Nucleotide numbering according to GenbankAccession' L76927 
The A~G transition at nucleotide position 303 is located in the GALKJ 5' UI'R, 
within the 250 bp putative eukaryotic polymerase II promoter region (Bergsma et al., 1996). 
Patient A is heterozygous for this sequence variant. 
Patient A is also heterozygous for a C---+T transition at position 7456 in intron 7. 
This is in close proximity to the 5' end of exon 8 of the GALKI gene, however it is not 
located within a recognized consensus branch splice site sequence or the splice acceptor 
site. The 2149T -+C nucleotide change in intron 2 is located 34 bp upstream of the 5' end 
of exon 3 and 3 bp upstream of a putative eukaryotic consensus branch point scquenct:, 
YNRAY {Chiara et al., 1996; Rautmann & Breathnach, 1985). Patient A was homozygous 
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for this intronic substitution. The same sequence variant was also found in the 
heterozygous state in another patient, with typical galactokinase deficiency, where two 
disease-causing mutations (f288M and 2833dclC) have been identified (Chapter 3, Section 
3.4.2). 
The only change found tn the codjng sequence of GALK1 in patient A, was the 
G-)A transition at nucleotide position 7087 (Figure 4.1) which results in the substitution 
of glutamine for arginine at codon 286 (R286Q) in exon 6 (Figure 4.2). Although arginine 
and glutamine djffcr in terms of side-chain charge, both arc hydrophilic amjno acids 
(Figure 4.3), suggesting that the substitution is unlikely to affect secondary protein 
structure. Indeed, secondary-structural analysis using the PHDsec algorithm (Rost & 
Sander, 1994) predjcts structural identity and no interference with the helix formed by tills 
fingerprint motif (Figure 4.4). 
GGGGG A G A TT C N GC GC A C G GCC 
G G G G G A G 1\ T T C G G C G C A C G G C C 
A 
(Genbank Accession #L76927) 
Figure 4.1 7087G-)A transition causing a R286Q substitution in exon six. 
Wild type 
Codon 283 284 285 286 287 288 289 290 
Amino acid G E I R R T A Q 
Nucleotide GGG GAG A1T CGG CGC ACG GCC CAG 
R286Q 
Codon 283 284 285 286 287 288 289 290 
Amino acid G E I Q R T A Q 
Nucleotide GGG GAG ATT CAG CGC ACG GCC CAG 
Figure 4.2 Residue change at codon 286 caused by the 7087G-)A transition. Wildtype 
arginine is replaced with glutamine . 
... 
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Figure 4.3 R286Q- molecular comparison between arginine and glutamine residues 
Galactokinase exon 6 wild-type 
280 . 290 
AA I~ K E G F R R A R H v v G E ( R R T A Q A A ~I PI-IDsec H H H H H H H H H H H H H H SUBsec L L L L H I-f H H H H H H H H H H H H H 
Galactokinase R286Q 
280 290 
AA I~ K E G F R R A R H v v G E I Q R T A Q A A "I PHDscc H H H H H H H H H H H H H H H H J-1 H SUB sec L L L L H H H H H H H H H H H H H H H 
Figure 4.4 Secondary·structure prediction for the wild-type exon six galactokinase 
sequence and the R286Q missense mutation using the PHDsec algorithm. Q286 in 
boldtype face. E - extended sheet (beta sheet); H - helix; L = loop. The prediction is 
meaningful for all residues with an expected average correlation > .69. 
This R286Q missense mutation occurs within the fourth, evolutionary conserved 
galactokinase fingerprint sequence (RRARHWGEIRRTAQ). However, a BLAST 
homology search comparing published galactokinase sequences of diverse species revealed 
that this particular position is highly variable: while an arginine residue occurs in the murine 
and human galactok.inase, glut~unine is the common amino acid at position 286, found in 6 
out of 20 galactokinases which share the fingerprint motif (Figure 4.5). 
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Gab.ctokinase motif four Or anism 
K R A R 1-I A v s E N Q R T L K Stn11ltrlrp5 InN/am 
K R .\ R H V v T E N Q R v L !) n.,mqJJilw i:njl11ov& 
K R v R Ill L T E N A R T v E [sdnilM coli 
K R v R Ill L T E N A R T v E Bacu:rioflxw !amMo 
K R v R II V L s E N A R T v E Sabnmd!d typhiniUTUf!11 
K R A K 1-1 I I s E N Q R v L E Actinohv:illmplarmpnamniae 
R A K H V y s E s L R v L K Saalurmrps U'n'lisiae 
K R A R H A v s E N Q R T I. R Laaolut:illm helu:tia1s 
R A K H v y s E A L R v L K K/uyu:rutrps fat:W 
R A K H v y Q E s L R v L E Cniida aUicans 
E R A L H v y R E s L R v L K Cniida pampsi/mis 
R R A K H A v y E N r R A I K Bacillm subtili.s 
K R A R H v v L E N Q R T L Q Stnpl.ot.roliS ~IJ 
R A K H v y s E s L R v L K SacdJcnWr;.ces ~iae (GA_l~!L _____ 
R R A R H v v G E I R R T 
A_Q ____ 
Hfn!J~----- ~--- -- ·----
' 
--R R A R H V v s E I R R T A Q Mm rrnooth1s 
K R A R H A v F E N Q R T L K LactolWllm casei 
K R A Q H V L E E N E R v L K n~ ""''X'i"'"" 
K F F G y I v R E N A R v L E Ppwx:oiS lnrikmbii 
R L v R H V v T E !) E R v E R S"'f'fm¥'> lrudmu 
Figure 4.5 Galactokinase fingerprint motif four. Bold highlight showing amino acid 
variation analogous to residue 286 of the hwnan galactokinase protein at which the R286Q 
substitution is found. Glutamine (Q) occurs in six of the galactokinases that share the 
fourth galactokinase fmgerprint motif. Motif alignment by SPRINT (available 
hrtp://www.bioinf.man.ac.ukldbbrowser/sprint/). 
The onlt difference found between GALKJ in patient Band the wild-type sequence 
was a G~A transition at nucleotide 1556 in exon 2. This change results in a silent 
mutation at codon 63 (L63L). 
Comparisons of the GALKJ sequence in both patients and unaffected controls with 
the published wild-type sequence (Genbank Accession • L76927) revealed a number of 
nucleotide discrepancies previously reported by Asada et a!. (1999) that were shared in all 
samples analyzed. These changes include a 41SC--tT and 418C--tT in the S'UTR, a 
694C--tT in intron I, as well as a 2130C--tG and 2132A--tC in intron 2 (Chapter 3, Table 
3.4). 
4.5 DISCUSSION 
71 
The unique characteristics of this condition, namely a markedly increased blood 
galactose concentration, bck of galactose-1-phosphate and normal RBC galactokinase 
activity, pointed to a rare disorder of the first step of galat:tose metabolism. The metabolic 
evidence of galactokinasc deficiency, together with the normal activity of this enzyme in 
peripher.tl blood cells, suggested a defect in tissue-specific galactokinase expression. The 
rarity of the disorder ;md the common ethnic background of the affected individuals 
suggested a common molecular defect. This study was therefore based on the hypothesis 
that the two patients wUl be homozygous for the same disease-causing founder mutation in 
the galacrokinase gene GALKJ. 
4.5.1 Sequence analysis 
Approximately 3.1kb of the GALKJ sequence were investigated, including all 
coding regions, at least 100 bp of the flanking intronic sequences and the 5' and 3' U1R 
This analysis failed to reveal any sequence variants that are plausible disease-causing 
mutations. Within the coding sequence, the 7087G~A transition identified in patient 1 
resulted in the non-drastic glutamine for arginine substitution at a non-conserved position 
in exon 6. In fact, this substitution reverted to the glutamine residue which is more 
common in the galactokinase protein of different species. These findings, together with 
the lack of effect on secondaty structure predictions, lead to the conclusion that R286Q is a 
polymorphism that is unlikely to c.-:.use the disease. The single exonic change found in 
patient 2, was a silent mutation at codon 63, i.e. again a neutral polymorphism. 
Patient 1 also displayed three additional nucleotide substitutions in the intronic 
sequence of the GALKJ gene. The 7456C~T transition in intron 7 does not affect a 
known consensus splice motif, nor does it seem to activate a cryptic splice site and thus 
appears to be a polymorphic variant. The other two nucleotide substitutions, at positions 
303 in the SUTR and 2149 in intron 2, could potentially affect the level of expression of 
72 
CALK! or the splicing of the primary transcript. The 303A~G change occurs in the 
putative polymerase II pmmoter sequence (Bergsma et al., 1996), whereas 2149T ____,C i~ 
located in close proximity to a putative eukaryotic branch point motif {Chiara ct al., 1996). 
\'\1llle expression studies are needed to investigate the hypothetical effect of these changes 
on CALK! expression, their likely role as neutral polymorphisms is supported by the fact 
that the same intronic substitutions have also been found to occur in a patient with typical 
galactokinase in whom both disease-causing mutations have been identified (Chapter 3, 
Section 3.4.2). 
The most significant finding of this analysis was the lack of similarity between the 
two patients. Both were heterozygous for nudeotide variation in CALK! and none of the 
nudeotide variants were shared between the two patients. The findings indicate that these 
two individuals, presenting with the same rare phenotype and originating from the same 
ethnic background, carry different copies of the known galactokinase gene. The results 
provide strong evidence against a role of CALK! in this condition. 
4.5.2 Other aberrations to galactose metabolism 
Although it is likely that this investigation excluded CALK! as the responsible gene, 
the possibility remains that both patients share an aberration in another gene involved in 
galactose metabolism. Supporting this possibility is evidence pointing towards the existence 
of multiple forms of the enzyme including both age-related and tissue differences in 
galactokinase expression levels (Ng, Donne!, & Bergren, 1965; Shin-Buerhring, Beier, Tan, 
Osang, & Schaub, 1977) and variation in kinetic and functional properties (Cuatrecasus & 
Segal, 1965; Mathai & Beutler, 1967; M.1gnani eta!., 1982b). Perhaps the most compelling 
evidence for multiple forms of the enzyme comes from clinical data of an adult who is 
homozygous for a known deficiency-causing mutation yet has intermediate erytlu·ocyte 
galactokinase activity analogous to a heterozygote carrier (Kalaydjicva et al., 1999). Whether 
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this discrepancy and the reported differences in the properties of galactokinasc arc due to 
the presence of two different genes or reflect post~translational modification of the same 
protein remains to be characterized. Identifying the mechanism(s) responsible for these 
observations may aid in detennining the cause of the persistently high levels of blood 
galactose that is associated with this new phenot:yi.- :. 
Alternatively, future directions for determining the genetic basis for this new 
phenotype include an analysis of other genes or processes that may play a role in galactose 
utilization. One likely candidate is the SLC2A2 gene (Genbank Accession ' 4557850) 
which encodes a hepatic facilitative hexose transporter {GLUT~2). The cellular uptake of 
galactose is made possible by the GLUf.2 transport mechanism capable of carrying both 
glucose and galactose across the hepatocyte membrane (Burchell, 1994). The fact that such 
receptors display different degrees of specificity for the two hexoses, suggests either 
inherent differences in the binding sites vf the transport protein, or may reflect variation in 
the efficiency of binding at the same site. Both pharmacological (Ibu & Shott, 1986) and 
physiological (Fiete, Brownell, & Baenziger, 1983) evidence indicates that galactose uptake 
at these receptors can be modulated, possibly signaling inherent differences in the substrate 
binding domain of the transporter {W"u, Fritz, & Powers, 1998). Mutations to a galactose· 
binding site would limit liver uptake, leading to an accumulation of galactose in the blod. 
If the sugar was present in high concentrations, the erythrocyte capacity to successfully 
phosphorylate galactose may become saturated, leading to further accumulation of 
galactose and subsequent initiation of the galactitol pathway. The production of a 
pathological level of galactitol would result due to the wide distribution of the galactose 
reducing enzyme, aldose reductase, found in a number of tissue sources including the lens 
of the eye (Segal & Beny, 1995). A defect to the hepatic galactose transport mechanism 
may possibly lead to an increase in blood galactose analogous to the biochemical 
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description of the patients in the currcm study. Both possibilities should be considered for 
further ~malysis in detem1ining the molecular aberration responsible for this phenotype. 
Other pathologies affecting galactose metabolism should also be considered. Two 
reports Qakobs et a!., 1988; Budde, Gusek-Schneider, Junemann, Jansen, & Shin, 1999) 
detail omother metabolic disorder affecting the galactose pathway called Shin-Jakob's 
disease. In this condition, subjects present with increased blood galactitol levels and 
cataracts without any identifiable defect to any of the three enzymes in the Leloir pathway. 
Jakobs et al. (1988) suggest these findings may be explained by three possibilities including 
an aberration to a fourth unknown galactose enzyme, a variant of a known enzyme or an 
increase in activity of the enzyme, aldose reductase. The molecular defect underlying these 
observations has yet to be elucidated. 
Segai {1998) suggests that the hypergalactosemia seen m some galactosemic and 
galactokinase-deficient sufferers, despite a restriction of galactose from the diet, may be 
attributed to endogenous sources of g<~lactose. This source includes the recycling of UDP-
galactose from cell membranes. If the enzymatic mechanism for this salvage process was 
over-expressed, it would cause a rise in blood galactose levels that may overload the 
functional capacity of galactokinase. 
4.5.3 Conclusions 
Although this analysis has excluded mutations in the known promoter region v.r:ithin 
the SUIR of the GALKl gene as well as the entire coding regions, flanking intron regions 
and the 3'UTR, functional expression studies and characterization of mRNA transcripts 
from both patients should be carried out in the future. Such investigations may identify 
differences in expression of galactokinase shared by these patients. These differences may 
possibly reflect the use of different splicing mechanisms or alternatively reflect the use of 
tissue-specific GALKl promoters not identified in our c11rrent knowledge of the gene. 
Testing for mutations in the SLC2A2 gene, which encodes the hepatic glucose/ galactose 
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tr.msporter, or linkage analysis arc other strategies that should be used in future studies to 
determine the cause of this phenotype. 
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CHAPTERS ANALYSIS OF THE ORIGINS, DISTRIBUTION AND 
FREQUENCY OF A COMMON GALJ(l MUTATION CAUSING 
GALACTOKINASE DEFICIENCY 
5.1 INTRODUCTION 
The P28T mutation has previously been identified as the common mutation causing 
galactokinase deficiency in six Romani families from Bulgaria (Kalaydjieva et al., 1999). 
Titese families originate from three socially distinct but genetically related groups; Kalderas, 
Rudari and Thracian Tinkers, whose migratmy patterns can be traced back to the northern 
part of the Balkans. Indeed the Vlax Roma, as they are collectively known, show a high 
number of affected births, with incidence in the range of 1:1600 to 1:2500 birrhs and based 
on the screening of 130 individuals, a predicted carrier rate of the P281' mutation, in the 
vicinity of 4%-5%. 
TI1e fact that the current investigation (Chapter 3, Section 3.3.3) has identified a 
number of patients from Gypsy groups geographically dispersed throughout Europe and 
socially and culturally distinct from the Vlax Roma, suggests that the distribution of the 
P28T mutation is more widespread than first thought. Establishing that the P28T mutation 
in these groups is shared common by descent and is not a recurrence of the same mutation 
at the same codon, will provide infonnation into the genetic origins and relatedness 
between such groups and will allow a study of the history of the mutation and the historical 
demography of the affected groups. At the same time, the identification of populations at 
high risk of infantile and perhaps presenile blindne.~s means that screening strategies and 
early intervention can be utilized to prevent the progression to sight impainnent caused by 
galactokinase deficiency in these groups. 
Two strategies need to be employed to achieve this. 11lis first is establishing the 
common origin of the P28T mutation. Previous haplotyping analysis in Bulgarian Romani 
families has identified a conserved haplotype surrounding the P28T mutation (Kalaydjieva 
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et al., 1999). The disease allele has been shown to be in strong linkage disequilibrium with 
allele 2 of the marker Dl7Si839, located at a small physical distance to G!ILKI. 
Identifying similar conserved regions of homozygosity will point towards a common origin 
of the P28T mutation. Evidence of historical recombinations in the diverse Gypsy groups 
will allow further studies of the history of the mutation. 
Establishing carrier rates by screening unrelated individuals for the P28T mutation 
will allow future prevention programs for infantile blindness such as newborn screening 
and dietruy intervention to be designed, and their cost~efficiency estimated. Furthermore it 
will allow future studies investigating the link to presenile cataracts to be conducted, based 
on the large numbers of carriers of the same mutation where other factors, eg. nutrition, 
can be taken into account. 
5.2 SUBJECTS 
5.2.1 Haplotype analysis determining the origin of the P28T mutation 
The study sample included 13 subjects (Table 5.1): six have been identified as homozygous 
for the P28T mutation (Chapter 3, Section 3.3.3) and seven unaffected family members. 
These patients derive from geographically dispersed regions throughout Europe including, 
Turkey, Spain and Hungary and all but the Turkish patient report Gypsy origins. All were 
small nuclear families, except for the consanguineous Spanish Gypsy kindred shown in 
Figure 5.1. In additien, control P28T homozygous, heterozygous and unaffected 
individuals derived from Bulgarian families were run in parallel for each of the markers. 
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Table 5.1 
Individuals with the P29T Mutation 
Individual P28T Genotype 
Homozygous 
Heterozygous 
Heterozygous 
Heterozygous 
Homozygous 
Heterozygous 
Homozygous 
Heterozygous 
Homozygous 
Homozygous 
Heterozygous 
Heterozygous 
Homozygous 
Origin 
Turkish 
Turkish 
Spanish Gypsy 
Spanish Gypsy 
Spanish Gypsy 
Spanish Gypsy 
Spanish Gypsy 
Hungarian Gypsy 
Hungarian Gypsy 
Hungarian Gypsy 
Hungarian Gypsy 
Hungarian Gypsy 
Hungarian Gypsy 
a University Ollldren's Hospital, Zurich, S'l'.itzerland 
b Institut Bioquimica Clinica, Barcelona, Spain 
' Dept. of P?.ediatrics, University Medical School, Szeged, Hungary 
C cenotes kindred 
5 
Figure 5.1 Pedigree of consanguineous Spanish Gypsy family. Individuals whose DNA 
was available for analysis are numbered. 
5.2.2 Population Screening for the P28T mutation 
The population distribution and frequency of the P28T mutation was analyzed in a 
sample of 227 individuals from socially and geographically diverse Gypsy groups. 91 of 
these belong to the Vlax Roma groups: 45 Rudari and 46 Lorn; 36 are derived from the 
79 
Xoroxane Gypsies; and 39 belong to other Gypsy groups from Bulgaria. In addition, 55 
Spanish Gypsies and 6 Lithuanian G;rpsies were also screened for the P28T mutation. 
These data were combined with the results of previous screening carried out at the Centre 
for Human Genetics, Edith Cowan University, of 144 individuals from Rudari, Lorn, 
Kalderas and Xoroxane Gypsy groups (Table 5.2). 
Table 5.2 
Individuals Screened for the P28T Mutation 
Previously This 
Population screened Study Total 
n n n 
Vlax groups 135 91 226 
Rudari 79 45 124 
Lorn 13 46 59 
Kalderas 43 43 
Xoroxone 9 36 45 
Others 39 39 
Spanish 55 55 
Lithuanian 6 6 
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5.3 METHODS 
5.3.1 Haplotype analysis 
5.3.1.1 Micmsatdlitcmarkers 
Six microsatellite markers (Table 5.4) spanning a 9cM region surrounding the 
GALl(J gene were chosen from a selection of markers used in a previous study to 
map the disease gene (Kalaydjieva et al., 1999). PCR amplification protocols and 
conditions are detailed in Table 5.4. Each reaction consisted of 2011g of DNA, 
0.2mM each primer, 0.25mM each c!NTP, optimal MgCI2 concentration (fable 5.4), 
I x PCR buffer, 0.2U of T aq polymerase and dH,O to a final volume of 1 0~1. 
Radioactive labeling was done through incorporation of 0.1~1 of u"P-dCTP 
(Gene Works cat • ADC-32U/L) in the product during PCR amplification. 
Table 5.3 
PCR Conditions and Protocols for Microsatellire Markers 
Marker Size PCR Conditions Additives 
01751797 183-193bp 1D 63oc ->55'{; 1.5r<1M MgCI, 
01751602 197-207bp 58"C !01 JS cycles l.SnlM MgCI, 
01751864 183-209bp 1D62" c --> 52•'C 1.5mMMgCI, 
0175929 217-229bp 1D 63"C ->55'{; 1.5mMMgCI, 
0!751839 237-245bp 1D 63"C ->55'{; 1.5mMMgCI2 
01751817 183-209bp 62'{; for 35 cycles l.OmMMgCI2 
5.3.1.2 El~isanpolyacrylomiderr! 
PCR products were electrophoresed on 6% polyacryhunide gels, prepared by 
adding 420.4g of {7M) Urea and 150mL of 40% 19:1 acrylarnide/bisacrylamide to 
SOOml of dH20. This solution was deionized for 30 minutes using mixed bead 
resin. The solution was then filtered and lOOmL of lOx TBE buffer we5 C<dded and 
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the final volume' made up to 1L with dH20. Prior to pouring, 130).11 of 12% APS 
(ammoniwn persulphate) and 130~1 of TEMED (N'N'N'N'-
' ' ' 
tetr-.m1Cthyl..>thylenediamine) were added to 60mL of polyacrylamide solution, 
mixed, then injected between two cleaned and damped glass plates. Well formers 
were inserted and the gels were left to set for 2 hours before fitting to the Hoefer 
Poker Face II SE1600 Sequencing Series apparatus. Upper and lower chambers 
were filled with 1 x TBE buffer and the gels were pre-warmed for 30 minutes at 
1400V. The well former was removed and a loading comb inserted before each well 
space was rinsed using a transfer pipette. lO)ll of formamide loading buffer (98% 
formamide, !OmM NaOH, 0.1% bromophenol blue & 0.1% xylene cyanol) was 
added to each PCR reaction and denatured for 5 minutes at 94 degrees C. Products 
were placed on ice and 2:-tl of each sample was loaded into single lanes of the gel. 
The gel was electrophoresed at 1400V for 2 hours. Plates were removed from the 
apparatus and the outer glass plate was lifted off using a plastic wedge. 
Approximately 200mL of fixer solution ( 10% methanol, 10% glacial acetic acid in 
dH20) was poured over the gel 3 times over a duration of 10 minutes. The fixer 
was then drained and a piece of chromatography paper was laid over the gel. The 
paper and gel were lifted of the glass plate, covered with plastic wrap, and allowed 
to dry on a Savant Slab Gel Dryer at 60 degrees C for I hour. Dried gels were 
exposed on Cronex' Medical X-Ray film {Sterlin~ Diagnostic Imaging) in fdm 
cassettes for approximately 14hrs at room temperature. The films were developed 
on aAGFA' CURIX 60 developing machine. 
5.3.1.3 Haplotype <UUdysis 
Allele scoring was done manually, usmg a lighthox. Alleles were numbered 
sequentially from top to bottom. To ensur~ compatibility of allele assignment with 
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the previous study, several individuals from the original Bulgarian Gypsy families 
(Kalaydjiev;t et a!., !999) were genotyped in parallel. Haplotypes were constructed 
manually. In case parental information was missing (One of the Hungarian Gypsy 
subjects), phasing was done by assigmnent of the most common haplotype to one 
of the chromosomes. 
53.2 Population screening for the P2BT mutation 
The 563C-)o A transversion (P281) abolishes an A val restriction site and thus a 
PCR-based restriction assay can be used for screening purposes. A 450bp DNA 
fragment spanning the region between nucleotides 358 and 808 in the GALKl 
sequence (Genbank Accession ' L76927) was amplified from genomic DNA and 
FfA cards by use of primers 5' -GGGGCGTCCGGGCGCGGGGC-3' and s'-
GACAGGCTGTTCCCCACGT-3' . PCR volumes were made up to 201'1 and 
consisted of 20ng of starting DNA for genomic samples, or a lmm x lmm section 
of FfA card. In addition, the PCR mixture contained 1.25mM of MgCI,, 2mM of 
each dNTPS, 1 x PCR buffer, 4% DMSO, O.SU of Taq polymerase and dH,O. 
PCR conditions included initial denaturation at 94 degrees C for 5 minutes, 
followed by 35 cycles of 94 degrees C for 30 seconds, 63 degrees C for 30 seconds 
and 72 degrees C for 40 seconds. This was followed by an additional extension step 
at 72 degrees C for 7 minutes. PCR products were sodium/ ethanol precipitated as 
described in Section 3.3.4 and resuspended in Sfll of dH,O. Products were cut with 
0.31'1 of the restriction endonuclease, Ava! [10 OOOU/ml] (New England Biolabs 
cat' R0152S), 1.51'1 of NE buffer, 1.51'1 of BSA and dH,O in a final volume of 
12.5f.ll. Products were incubated at 37 degrees C for 3 hours before electrophoresis 
upon 4% agarose/EtBr gel at 60V for 1 hour. Digests were visualized on a Hoefer 
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Mighty Brightn' UV Illuminator and the image was recorded usmg a Kodak s 
DC120 digital camera and Kodalt Digital ScicnceTM software. 
Carrier frequency was determined by counting the number of affected alleles 
detected and compared with carrier frequencies calculated from a similar screening 
strategy carried out previously at the Centre For Human Genetics, E.C.U. 
5.4 Results 
5.4.1 Haplotype analysis 
Haplotype amolysis revealed complete homozygosity for marker D17S!839 for mutant 
chromosomes across Europe (Figure 5.2 & 5.3). Allele 2 of this marker was present in all 
chromosomes with the P28T mutation and has previously been shown to be in strong 
linkage disequilibrium with the P28T mutation among six Bulgarian Gypsy families 
(Kalaydjieva et al., !999). The fact that the Hungarian Gypsy patients, Spanish Gypsy 
patients and the Turkish patient are also homozygous for this allele in conjunction with 
P28T, points towards a common founder mutation. 
A highly conserved haplotype common to the haplotype seen in the Bulgarian Gypsy 
families, was carried by 5 chromosomes in 4 Hungarian Gypsies and 1 Spanish Gypsy 
(Figure 5.2). The alleles seen in the rest provides evidence of different historical 
recombination which would be expected, given that the sample of patients analyzed 
originate from dispersed groups. 
Allele 2 of the D17S!839 marker was not found in any of the Bulgarian, Hungarian 
and Turkish control individuals, not carrying the P28T mutation. This provides further 
evidence that this particular allele is in strong linkage disequilibrium with the disease 
mutation. 
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Figure 5.2 Pecligrees and marker haplotypes for patients with P28T. a) Turkish. 
b) Consanguineous Spanish Gypsy kindred. c-e) Hungarian G ypsy. Red highlight 
inclicates conserved haplotype. Bold red highlight indicates conserved allele 2 of 
marker D17S1839. 
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Figure 5.3 Marker haplotypes in the 17 q24 region of disease chromosomes from 
Bulgarian Gypsy groups •(Kalaydjieva et al., 1999) (upper map) and current study 
sample consisting of Spanish, Hungarian and Turkish Gypsies Qower map). Allele 2 
of marker D17S1839 is shared in all chromosomes with the mutation. 
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5.4.2 Poprtlation screening and Carrier Frequency of P28T 
The PCR~based Aval restriction assay of 227 individuals detected one homozygou;; 
affected individual belonging to a Vlax Roma group and one heterozygous carrier from the 
Spanish Gypsy group. Carrier frequencie> (Table 5.4) in both these populations were 
calculated by the number of affected alleles detected, thus giving a carrier rate of 2.2% in 
the Vlax Roma population and 1.8% in the Spanish Gypsy population. 
The homozygous individual is of Rudari origin and when combined with previous 
screening data, the carrier frequency within the Rudari group to date is 3.2%. As with 
previous fmdings, no carriers of the P28T mutation were detected among the Lorn 
population. Previously, carrier frequency in the Kalderas has been found at 4.6%. Although 
individuals from this group were not available for screening in the current investigation, it 
seems that both the Rudari a.1.d Kalderas groups are major contributors to the overall 
carrier frequency of the P28T mutation seen in the Vlax Roma, which from the current 
analysis stands at 2.7%. No carriers were detected in the Xoroxone group nor within the 
small number of Lithuanian Gypsies analyzed. 
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5.5 DISCUSSION 
5.5.1 Haplotypes 
It is evident that the P28T mutation detected in Bulgarian, Spanish and Hungarian 
Gypsy patients as well as the Turkish patient is the founder mutation reported in 'lix 
Bulgarian families (Kalaydjieva et a!., !999). The identification of a shared region of 
homozygosity surrounding the D17Sl839 marker in all patients with the P28T mutation 
signifies a common origin. The fact that allele 2 of the D17S1839 marker was not seen in 
individuals without the P28T mutation also lends further support that the disease allele is in 
strong linkage disequilibrium with this allele. 
It is interesting to note that the haplotype analysis has revealed that the P28T 
mutation carried by the Turkish patient, is in fact the same founder mutation common to 
Bulgarian, Hungarian and Spanish Gypsy groups in the study. It is likely that the ethnicity 
of this patient and mother is obscured perhaps to avoid the racial and social persecution 
and prejudices historically aimed at the Gypsy population. The high degree of 
polymorphisms in the haplotype pattern evident in this patient, as compared to other 
patients, may reflect historical recombinations resulting from the divergence of Turkish 
groups away from a common Gypsy origin or alternatively may indicate admixture. 
5.5.2 Population screening and Carrier Frequency of P28T 
The detection of a heterozygote carrier in the population screening of the Spanish 
Gypsy group, combined with the findings of the common founder mutation in patients of 
Spanish and Hungarian Gypsy descent, highlights the widespread distribution of the P28T 
allele. Tbis infonnation is not only important for the development of intervention 
strategies targeting groups at risk of infantile and presenile blindness but also paves the way 
for anthropological studies perhaps investigating the historical origins and diversification of 
the many Gypsy groups. 
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5.53 Conclusions and future directions 
Both the detection of a heterozygot< carrier through screening of the Spanish Gypsy 
population ;md the haplotype analysis of a Spanish Gypsy kindred suggest that the 
incidence of the P28T mutation is widespread throughout Europe. Additional dat:.\ need to 
be collected for the Spanish Gypsy population, before newborn screening is initiated. For 
the time being, galactokinase deficiency should be considered in any patient of Gypsy 
ethnicity with infantile cataracts and the P28T mutation provides an easy test. The 
mutation test can be incorporated in the existing newborn screening in Hungary and 
Bulgaria to replace the current lengthy procedure of diagnosing galactokinase deficiency by 
metabolic and enzyme assays. Finally, large numbers of adult carriers can be identified by 
either cascade testing in the families of affected children or by random population 
screening. These subjects can then be studied funher to clarify the proposed link between 
panial galactokinase deficiency and presenile cataracts. 
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CHAPTER6 SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
Conclusive infonnation regarding the molecular basis of galactokinase deficiency and 
galactose metabolism is far from complete. The mechz.nisms underlying the discrcpancie!; 
that exist between galactokinase activity and properties in relation to factors such as age, 
tissue and allelic heterogeneity, are still unclear. Atypical clinical observations further 
confound existing ideas about the function and role of galactokinase in galactose 
metabolism. This is evident from the clinical descriptions provided in Chapter 4 of patients 
with a rare galactokinase deficiency phenotype, characterized by increased blood galactose 
levels, yet normal enzyme activity in RBCs, as well as the observations of an adult with 
intermediate galactokinase activity despite being homozygous for a known deficiency· 
causing mutation (Kalaydjieva et al., 1999). Perhaps these observations signal the existence 
of mulciple forms of the enzyme or even multiple mechanisms and/ or pathways of 
galactose metabolism. Whether these are the result of an enzyme encoded by separate 
genes or reflect differences in post-translational modifications and/ or alternative regulation 
of expression of the same gene product, remain to be clarified. Furore steps which need to 
be taken to address these possibilities, include extensive mRNA comparisons, 
enzymological characterization, or haplotype analysis. The outcomes from these 
investigations may not only complete our nnderstanding of galactose metabolism but also 
benefit the treatment of patients. For instance, recognizing heterogeneity in expression or 
activity as a function of age would have implications as to the extent and duration of 
dietruy intervention in affected individuals. 
The current investigation has added 4 novel molecular defects: R68C, T288M, 
A384P and 2833delC to the allelic heterogeneity of GAL!(J mutations. Despite the lack of 
expression analysis in this study, it is likely these are disease-causing mutations due to the 
nature of the mutations, the fact that they occur in conserved residues and did not occur 
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among 100 normal chromosomes. While the identification of additional GALKJ mutations 
in individuals with galactokinase deficiency should ultimately contribute to understanding 
the functionally important domains of the galactokinase protein and the molecular basis of 
the disorder, the rarity of the individual defects and the compound heterozygous state of 
most patients, suggest that meaningful studies of genotype/phenotype correlations in the 
affected individuals are not feasible. It is the founder mutations, in the homozygous and in 
the carrier state, that will allow such studies, as well as research into the role of partial 
galactokinase activity as a factor predisposing to presenile cataracts. 
The findings of a common origin, carrier frequency and distribution of one such 
founder mutation P28T, amongst dispersed Gypsy populations, have impl.;cations for the 
development of newborn screening programs and dietaJY intervention to prevent the 
incidence of infantile blindness in susceptible groups. The results also pave the way for the 
future identification of large sample numbers of both homozygotes and carriers in order 
for extensive genotype/phenotype correlations to be investigated. This will ultimately 
contribute to the complete characterization of the role galactokinase plays in galactose 
metabolism and the molecular basis of the deficiency phenotype. 
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Communicated by Haig Ka:a:ian 
Galactoklnase deficiency is an inborn error of galactose metabolism whose major clinical 
manifestation is the development of cataracts during the first months of life. Only 20 
mutations have been reported to date and understanding or the functionally important 
domains of the galactokinase protein is still limited. Here we report four novel mutations in 
GALKJ that were identified in two unrelated patients with galactokinase deficiency. Three 
of these were amino acid substitutions: t569C---)T in exon 2 {R68C); 7093C~T in exon 6 
(T288i\f) and 7538G~C in exon 8 {A384P). In addition, ~single base-pair deletion was 
found in ex on 5 (2833deiC), predkted to result in a shift of the reading frame and a 
premature termination codon at position 263. Some differences with the GALKI sequence 
deposited in Genbank are also reported.{~_:. 2000 Wiley-Liss, Inc. 
KEY WORDS: Galactokinase deficiency, CALK I, galactosemia, galactose metabolism, cataracts 
INTRODUCTION 
Galactokinase (E.C.2. 7.1.6) catalyses the conversion of galactose to galactosc-1-phosphatc, the first step of the 
Lcloir metabolic pathway through which galactose enters glycolysis. Galactokinase deficiency (MIM# 230200) is 
an autosomal-recessive disorder whose metabolic consequences include a dramatic elevation of blood galactose 
concentration, galactosuria, lack of or greatly diminished production of galactosc-1-phospatc and activation of an 
alternative pathway of galactose metabolism, leading to the production of galactitol (Gitzelmann. 1965). The 
clinical phenotype is confined to the development of cataracts in affected infants during the first months or even 
weeks of life, as a result of the accumulation of galactitol in the lens of the eye and subsequent osmotic disruption 
of the lens fibers. Galactokinase deficiency can be diagnosed in the newborn period by hypergalactosemin 
screening and its consequences arc fully preventable by galactose-restricted diet. II has also been suggested that 
partial deficiency of galactokinase activity in heterozygous carriers may contribute to susceptibility to presenile 
cataracts (Stambolian et al., 1986). 
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2 llunt{'r l't al. 
The gen.: encmiing human galactokinase, G.·ILKI, was cloned in 1')!)5 and mapped by in-.1i/11 hybridization to 
the long ann ~1f chromosome 17 (Stambolian ct al., llJ!JS). l.inkagc analysis in affected Htmilics and radiation 
hybrid mapping have subsequwtly been used to refine its po~ition to a I eM region on 17q24 (Kalaydjicva ct a!., 
191)9). The );:l'llC spans approximately 7.3kb of genomic DNA and consi~t~ of eight cxuns cnwding a protein of 
3')2 amino acid residues (Bergsma et al., 1996). Apart from two putative AlP-binding motifs cncmlcd hy ex on~ 3 
anll7, understanding oft he structure oft he galactokinasc protein and its functionally important domain~ i~ still 
poor, partly due to the limited number of studies addressing the genetic basi~ of galactokinasc deficiency. 
Here we report four novel probable disease-causing mutations identified in two unrelated Cauca~ian individuah 
with galactokinasc dcticiency. 
METIIODS 
The affected individuals, one female and one male now aged 4 and 17 years, were detected a-; hypergalacto~cmic by 
newborn screening. Ga\actokinase deficiency(< 5% of the lower limit of the nonnal range) wa~ con finned by enzyme 
activity measurements in red hlood cc11s (RBC). The patients arc on galactosc-rc.\tricted diet and arc symptom-free. 
The search for mutations in GA.LK I was pcrfonncd on genomic DNA, by PCR amplification and direct sequencing of 
both strands of the 5' and 3' UTR. a11 coding regions of the gene and at least 100 bp of flanking intronic sequences. The 
primers used for the analysis of the untranslatcd regions were: for the 5'UTR 5'-CTGATGACCTCTCACAGCTGC-3' and 
5'-CTGTCTCAAAGCAGCCATCACG-3', and for the 3'UTR 5-GCTGTGCTTGTGAGGCACC-3' and 5'- CTICCAAA 
CTTGACCGCACCCT-3'. Exons and flanking intronic sequences were analysed as described (Kalaydjicva et al., \999). 
PCR reactions were made up to SO )11 and consisted of 2011g of genomic DNA, Jx PCR Buffer, l.SmM ~gC12 , 1.2SmM 
dNTPs, 4% DMSO, 2mM of each primer and 0.5 U ofTaq. Cycling conditions included initial denaturation at 94°C for 5 
minutes, 35 cycles of94°C for 30 sec, 63°C for 30 sec and 72°C for 45 sec, and final extension at 72°C for 7 minutes. 
Sequencing was performed using the ABI Prism Big DyeTM Tenninator Cycle Sequencing Ready Reaction Kit and the 
reactions were run on an ABI Prism 377 automated DNA Analyzer. Data processing was done using Sequence 
NavigatorTM (PE Biosystems), where the patient sequences were compared to unaffected controls run in parallel, and to the 
published GALKJ sequence (Gcnbank Accession# L76927). Searches of the public domain genomic databases were 
performed using the BLAST program [available at http://www.ncbi.nlm.nih.gov/ BLAST/]. Computer modeling of the 
predicted structure of the mutant protein was done with the PHDsec software (Rost & Sander, 1994) available at 
[http://dodo.cpmc.eolumbia.edu/ predictprotcinlsubmit_def.html]. 
A panel of 50 unrelated adult healthy Caucasian controls was tested for the presence of the putative disease-causing 
mutations by PCR-based restriction assays. 
The nucleotide numbering provided below is according to Genbank Accession# L 76927. 
RESULTS 
Both individuals were found to be compound heterozygotes for different molecular defects, none of which has 
been described previously: patient I presented with two missense mutations, R68C and A3R4P, and patient 2 
carried one missense, T288M, and one frameshift mutation, 2833delC. 
~ 
A 1569C~T transition in cxon 2 is predicted to result in the replacement of arginine by cysteine at codon 68. 
R68C is the fourth mutation described in exon 2, the remaining three being truncating mutations (Stambolian et al., 
1995; Kolosha et al., 2000). The arginine residue at this position is strictly conserved in the galactokinasc protein 
of over twenty different species checked, including the mouse. The mutation is a drastic change from a charged to 
an uncharged amino acid residue with a sulfhydryl side-chain, however the computer predictions did not suggest 
significant alterations in the secondary structure of the mutant protein. The 1569C~T transition creates an Alw Nl 
restriction site. The PCR-bascd restriction assay, used as a screening test, failed to detect the mutation among 100 
control chromosomes. 
A384P 
The 75380-R: transversion found in ex on 8 leads to the substitution of proline for alanine at position 3 84. 
A384P is located 8 amino acid residues upstream of the carboxyl terminus of the protein and is the second reported 
mutation in cxon 8, after Q382X (Kolosha ct al., 2000), suggesting that the carboxytcrminal part of the protein is 
essential for galactokinase function. Alanine at this position is not highly conserved, it is present only in the two 
(OAI.KI mulltthms 3 
m:ttntn>llian gal>~ctnkinasc~ charac:criscd so far, human :.~nd moust', and se4uencc similarity is found in the prokins 
of.so:ven additional species. The substitution nfpro!ine !i>r :tll111ine is likely to inUuce ~igni!icant topolo~;ical 
changes, as predicted by the secondary structural analysis. The helix formed hetwccn the J-"37X and A3H4 residues 
in the wild-type protein is abolisho:d by the mutation, which abolcaUs to an extension oft he beta sheet and cause~ 
loop fom1ation by >Hijaeent residues (Figure l ). The mutation abolishes a Ahv I restriction site. The restriction 
assay !:tiled to detect AJ4NI' amon~ the 50 cnntml indivitluals. 
Galactokinase, wild-t~·pe sequence 
370 3XO :wo 
AA E H y G G T A T F y L s Q A ,, D G A K v L c L 
PH Osee H H E E H H H H H H H E E E E 
SUB~cc H H L L L L L L 
Galactokinasc A384P 
370 . 3XO ]()[) 
AA E H y G G T A T F y i. s Q A p D G A K v L c L 
PH Osee H H H E E E F. E E E E E E 
SUBscc H H H E E E E E L L L L L 
Figure I Secondary-structure prediction for the wild-type exon eight galactokinase sequence and the 
A:84P missense mutation using the PHDsec algorithm. P384 in boldtype face. E "' extended sheet 
(beta sheet); H = helix: L "' loop. The prediction is meaningful for all residue> with an expected 
average correlation> .69. 
illftM 
A 7093C--+T transition causes the substitution of methionine for threonine at codon 288. T288M i~ the first 
mutation identified in cxon 6 of GALKI. encoding a conserved galactokinase fingerprint motif whose function is 
currently unknown. As shown by the sequence alignment of this galactokinase motif (Figure 2). the threonine 
residue at position 288 is conserved in nine out of twenty galactokinases. The mutation results in the replacement 
of a polar amino acid residue by a nonpolar with a sulfur-containing sidechain. Secondary structuml predictions 
are inconclusive. The mutation was tested in the panel of control individuals using a restriction assay (Nla Ill site 
abolished by the mutation). It was not found among 100 normal chromosomes. 
2833deiC 
A single base-pair deletion, 2833de\C, was found in exon 5, where one missense and another truncating 
mutation have been reported previously (A..<iada ct a\., 1999; Kolosha et al., 2000). Th~ 2833dc!C mutation is 
predicted to result in a frameshifl and a premature termination signal at codon 263, leading to a protein that is 130 
amino acids shorter than the wild-type enzyme. The presence of the deletion was independently confimted by 
single strand conformational polymorphism (SSCP) and heteroduplcx (HDA) analysis. 
In addition, we have detected a number of differences to the sequence published under Genbank Accession# 
L 76927 (Table 1 ). They were found in both affected individuals and unaffected controls (n"'9) of Caucasian and 
Afro/Hispanic descent in the present study, as we11 as in the Japanese and Caucasian individuals reported by Asada et al. 
(1999). 
Table t. Nucleotide Differences from Published GALKI Sequence GenBank Accession# L 76927 
Region Position Nucleotide Nucleotide Nucleotide 
5'UTR 
S'UTR 
Intron I 
lntron 2 
(L76927) (L76927) (this study) n=9 (Asada ct ill\999) n=7 
415 C T T 
418 C T T 
694 C T T 
2149 C G G 
4 lluntt'r t'f •1. 
lntmn2 ~ 151 A (' ( 
IHSCUSSION 
lh~ incidence ~1f galactokinase delicicncy, as reported hy newborn .~crc!.'ning programs in Europe, the United 
States and Japan, mnges between I: 150,000 and I: l ,000,000 (Levy, 19HO; Gitzclmann & llanscn, 19HO). The low 
frequency of th~.-• disorder has imposed limitations on research into the genetic cuuscs of gulactokinasc deficiency, 
resulting in a small number of reported mutations in CALK 1. Moreover, the small number of definite carriers that 
can be identified by mutation dctcctior, precludes studies addressing the proposed role ofpanial galactokinasc 
deficiency in the development of the common fonns of presenile cataracts. 
Galaeto masc moll OU< k' ·r~ Species 
K R A R H A v s E N Q R T L K Srrepromyces lividan.~ 
K R A R H v v T E N Q R v L D Haemophilus injluenure 
K R v R H I L T E N A R T v E Escherichia coli 
K R v R H I L T E N A R T v E Bacteriophage lambda 
K R v R H v L s E N A R T v E Salmonella typhimurium 
K R A K H I I s E N Q R v L E A ctinobaci flus pleuropnewnoniae 
Q R A K H v y s E s L R v L K Saccharomyces cerevisiae 
K R A R H A v s E N Q R T L R Lactobacillus he/veticus 
Q R A K H v y s E A L R v L K Kluyveromyces lactis 
Q R A K H v y Q E s L R v L E Candida a/bicans 
E R A L H v y R E s L R v L K Candida parapsi/osis 
R R A K H A v y E N H R A I K Bacillus subtilis 
K R A R H v v L E N Q R T L Q Streprococcus thermophilus 
Q R A K H v y s E s L R v L K Sacdwromvces cerevisiae (CAL3) 
R R A R H v v G E I R R T A Q Homo sapiens 
R R A R H v v s E I R R T A Q Mus musculus 
K R A R H A v F E N Q R T L K Lactobacillus casei 
K R A Q H v L E E N E R v L K Thermotoga neapolitana 
K 
R 
F F G y I v R E N A R v L E Pyrococcus lwrikoshii 
L v R H v v T E D E R._;: E R Streptom)'Ces fil'idans 
Figure 2. Galactokinase fingerprint motif four. Bold highlight shows amino acid variation 
analogous to residue 288 of the human galactokinase protein at which the T288M substitution is 
found. Threonine at this residue is conserved in 9 of 20 organisms. Methionine at this residue is not 
shared by any of the galactokinases that share the fourth galactokinasc fingerprint motif. Motif 
alignment by SPRINT (available at hnp:l/li'\'_-· .v.bioinf.man.ac.ukl dbbrowser/sprintl). 
A total of twenty GALKI mutationr associated with the galactokina~c deficiency phenotype have been 
identified to-date (Stambolian ct al., 1995; Asada et al., 1999; Ka!aydjieva ct a!., 1999; Kolosha ct al., 2000). 
Except for two founder mutations, namely P28T which occurs among the Vlax Roma (Kalaydjicva et al., ! 999) 
and Q382X found in patients of Costa Rican!Europcan descent (Kolosha ct al., 2000), the remaining aberrations 
are private mutations, confined to individual families. Similar to most individuals with galactokinasc deficiency 
described previously, our patients were also found to be compound hctcrozygotes, adding four novel molecular 
defects to the allelic heterogeneity of GALK 1 mutations. The lack of other changes in the CALK I gene, the nature 
of the detected sequence variants and their predicted effect on the protein, lead us to suggest that these are disease-
causing mutations. Including the mutations identified in this study, the overall distribution to-date is 14 amino acid 
substitutions and 10 truncating mutations, with exons 1, 2 and 7 harbouring 13 of the known mutations. The 
majority of missense mutations cluster in close proximity to the galactokinasc signature sequence in cxon land the 
(;AI.KI mu1111lnn~ 5 
second ATP-bimling domain in cxun 7, highlighting the functional ~ignificancc ofthc~c region~ for the crv:ymc 
activity. 
While the iJcntilkation of <ultlitional GALK I mutations in individuab with galactokinase dclkicncy ~huuld 
ultimatc\y contribute to understanding the functionally important domains of the galactokina~c rrotcin, the rarity 
of the individual defects and !he compound heterozygous slate of most patient.~. suggc.~t that meaningful .~ludic~ of 
genotype/phenotype correlations in the affected individuals arc not fi:asiblc. It i~ the fi:JUndcr mutation~. in the 
homozygous and in the carrier state, that will allow such ~tuJics, as well as research into the role of galactokina~e 
detidency as a Htctor predisposing to the common presenile cataracts. 
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